

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 December 2004 (02.12.2004)

PCT


(10) International Publication Number  
WO 2004/104041 A1

- (51) International Patent Classification<sup>7</sup>: C07K 14/705, 14/72, G01N 33/68, 33/566
- (21) International Application Number: PCT/GB2004/002150
- (22) International Filing Date: 18 May 2004 (18.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/472,025 20 May 2003 (20.05.2003) US
- (71) Applicant (for all designated States except US): THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow G12 8QQ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MILLIGAN, Graeme [GB/GB]; Davidson Building, University of Glasgow, University Avenue, Glasgow G12 8QQ (GB). BEHAN, Dominic [US/US]; Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, CA 92121 (US).
- (74) Agents: FORREST, Graham et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: MATERIALS AND METHODS RELATING TO G-PROTEIN COUPLED RECEPTOR OLIGOMERS

### Reconstitution of function by pairs of mutants



(57) Abstract: The invention provides materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Complexes of two or more GPCRs associated with G-proteins are provided. Also provided are fusion proteins comprising a GPCR and a G-protein, nucleic acids, expression vectors and host cells. Methods of producing the complexes and fusion proteins of the invention are also provided.

WO 2004/104041 A1



**Declaration under Rule 4.17:**

- *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

Materials and Methods Relating to G-Protein Coupled  
Receptor Oligomers

Field of the Invention

5 The present invention concerns materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Particularly, but not exclusively, the invention provides biological reagents comprising the GPCR oligomers, methods of producing said biological reagents and assays  
10 for determining their function. The invention also provides assays for determining compounds that have the ability to modulate the function of GPCR oligomers, particularly hetero-oligomers.

15 Background of the Invention

GPCRs are one of the largest gene families in the human genome and have been the most tractable set of targets for the development of clinically effective, small molecule, medicines. It is estimated that of the drugs  
20 used clinically in man some 40% target GPCRs. There is thus great interest in the details of the structure, regulation and activation mechanisms of GPCRs as well as the downstream signalling cascades they control. The class A or rhodopsin-like family of GPCRs is by far the  
25 largest containing more than 80% of the total GPCR family members. More than 800 genes encoding GPCRs have been identified in the human genome sequencing programme but only some 25 of these are currently the target for clinically effective medicines. There is thus great  
30 potential to expand this and to find useful medicines that target recently identified GPCRs (Lee et al., 2001).

In the recent past, the concept that GPCRs exist as dimers has moved rapidly from hypothesis to clearly accepted (see Bouvier, 2001, Milligan, 2001, George et al., 2002 for reviews). Although homodimers (i.e. a dimer containing two copies of one individual GPCR) have been the best studied, growing evidence suggests that heterodimerisation (ie. the dimer consists of one molecule of each of two different GPCRs) both occurs and can have both functional and pharmacological sequelae (Devi, 2001, George et al., 2002). However, important questions remain in relation to the selectivity of formation of such heterodimers and how to monitor the function of a heterodimer in isolation when co-expression of two different GPCRs must also result in the production of homodimeric pairs. Given that many GPCRs are co-expressed in a single cell then it is likely that the complement of GPCR dimers in a cell is complex.

Studies have been carried out on the  $\gamma$ -aminobutyric acid (GABA) type B receptor (GABA<sub>B</sub>R) (Duthey et al., 2002). This is an unusual GPCR because it is the only one known to date that needs two subunits, GB1 and GB2, to function. The GB1 subunit contains the GABA binding site but is unable to activate G-protein alone. GB2 does not bind GABA but does have the ability to activate G-proteins. Duthey et al. looked at the role of each subunit within the GB1-GB2 heteromer in G-protein coupling. The study included introducing mutations into both GB1 and GB2, particularly within the third intracellular loop. They determined that mutation to GB2 prevents G-protein activation, whereas a similar mutation to GB1 did not affect receptor function. Although interesting for the GABA<sub>B</sub> receptor, this study

unfortunately does not provide any information on GPCRs where the same protein is responsible for both ligand binding and G-protein activation.

5 Further studies looked at the co-expression of a first mutant receptor which was defective in hormone binding and a second mutant receptor which was defective in signal generation. It was reported that co-expression of the two mutants rescued hormone-activated cAMP production  
10 (Lee et al., J. Biol. Chem. Vol. 277, No. 18, 2002; Osuga et al., J. Biol. Chem. Vol.272, No. 40, 1997).

However, although it is acknowledged that GPCRs are extremely important as potential drug targets, there does  
15 not exist a satisfactory screening assay which allows reliable data to be gathered about the functional properties, e.g. ligand binding properties, of potentially naturally occurring GPCR oligomers, particularly GPCR hetero-oligomers.

20

#### Summary of the Invention

The present inventor has surprisingly found that, following ligand binding, a GPCR has the ability to activate a G-protein that is associated with a second  
25 GPCR, in situations where both GPCRs have formed an oligomer.

Specifically, and as illustrated by the examples given below, the inventor has found that co-expression in a  
30 cell of (A) a fusion protein of a GPCR and a G-protein where the GPCR is rendered non-functional with respect to the G-protein and (B) a fusion protein of a GPCR and a G-protein where the G-protein is rendered non-functional,

i.e. cannot act on a signal received by the GPCR, produces the following complexes, A, B, AA, BB, AB and BA where only AB and BA are functional, i.e. G-protein is activated to bind GTP and initiate the GPCR signalling cascade.

The basic strategy takes advantage of the fact that GPCR/G-protein  $\alpha$  subunit fusion proteins (Milligan, 2000; Milligan, 2002) can be considered as bi-functional polypeptides containing the sequences and the functional properties of both elements ie. the GPCR and the G-protein. By generating pairs of distinct mutants in which the first is mutated in the GPCR to render it incapable of activating a wild type G-protein to which it is fused and the second is mutated in the G-protein such that it cannot be activated by a wild type GPCR linked to it, the present inventor demonstrates that function may be restored when the two mutants are co-expressed. Thus, only the oligomer comprising at least each mutant produces functional complementation and is able to generate a signal in response to agonist ligands.

The inventor has appreciated that this phenomenon can be utilised to provide reliable screening assays to determine the properties of GPCR oligomers, particularly hetero-oligomers, and to provide biological reagents for using in such assays.

Thus, at its most general, the present invention provides materials and methods for determining the functional properties of GPCR oligomers, including determining potential ligands. The term GPCR is well understood in the art and refers to any cell surface trans-membrane

protein, that when activated by a suitable compound, in turn activates a guanine nucleotide-binding protein (G-protein).

5 In a first aspect of the present invention, there is provided a biological reagent comprising a GPCR oligomer having

(a) a first GPCR associated with a first G-protein wherein the first GPCR is non-functional with respect to  
10 the associated first G-protein;

(b) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional.

By the term "non-functional" it is meant that, in  
15 contrast to the wild-type, the protein (GPCR or G-protein) is not able to carry out a particular biological function. Thus, the fact that GPCR is non-functional with respect to G-protein means that it is incapable of carrying out its wild type biological function with  
20 respect to G-protein, namely, to activate G-protein following ligand binding. Other biological functions characteristic of the wild type (e.g. ligand binding) are preferably maintained.

25 Likewise, the non-functional G-protein is incapable of carrying out its wild type biological function, namely, initiating a cellular signalling cascade following stimulation from the GPCR.

30 The ability of the first and second GPCRs to form an oligomer, brings the functional second GPCR into the environment of the functional first G-protein. The functional GPCR is then able to activate the functional

G-protein which in turn brings about the cellular signalling cascade.

The first and second GPCRs may be the same, i.e. a homo-oligomer, e.g. a homodimer, homotrimer or higher order oligomer, or the first and second GPCRs may be different, i.e. a hetero-oligomer, e.g. a heterodimer, heterotrimer or higher order oligomer.

Ideally, the oligomer is present in a cell membrane. This may conveniently be achieved if the first and second GPCRs and their associated G-proteins are co-expressed in the cell. Thus, ideally the GPCRs and their G-proteins are associated with each other as fusion proteins. However, the skilled person will appreciate that other means of association are possible. For example, the proteins may be brought together by coupling means such as binding pairs, chemical bonds etc, or simply by natural association in a cellular environment.

The present invention also provides a mutant GPCR/native G-protein fusion protein for use in producing a biological reagent in accordance with the first aspect, and particularly for use in the methods according to the present invention (i.e. comprising a modified non-functional GPCR/functional G-protein), as well as a corresponding nucleic acid construct. Minor modifications may be carried out to the protein sequence, for example, an epitope tag may be added to the N-terminus of the receptor, a spacer segment introduced, in order to create a gap between the GPCR protein sequence and the G-protein sequence and/or a terminal methionine of the G-protein gene removed. Many such modifications

may be envisaged by the skilled addressee providing the functionality in use of the receptor/G-protein fusion protein remains substantially unaffected.

5 Further, the present invention provides use of a mutant GPCR/G-protein fusion protein, as described herein, in the methods according to the present invention (i.e. comprising either a modified non-functional GPCR/functional G-protein, or functional GPCR/non-  
10 functional G protein).

The nucleic acid constructs of the present invention comprise nucleic acid, typically DNA, RNA, mRNA or cDNA encoding the particular receptor to which is fused, in-  
15 frame, the appropriate nucleic acid sequence encoding the G-protein. Generally speaking the nucleic acid constructs are expressed in the cells by means of an expression vector.

20 Accordingly, there is also provided a cell comprising a GPCR oligomer having

(a) a first GPCR associated with a first G-protein wherein the first GPCR is non-functional with respect to the associated first G-protein;

25 (b) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional.

Typically, the cells are of eukaryotic origin, including yeast, such as vertebrate origin, including amphibian,  
30 and mammalian (especially human) and the expression vector chosen is one which is suitable for expression in the particular cell type. Suitable cells and expression vectors are discussed in more detail below.

In order that the biological reagent can be used in assays to determine the natural properties of the GPCRs oligomers, it is important that any ligand binding sites present on the GPCRs are maintained. Thus, it is preferable that the first GPCR is rendered non-functional only with respect to the associated first G-protein. In other words, the first GPCR maintains any ability it had to bind ligand but is incapable of activating G-protein following ligand binding. Of course, the actual combination of the GPCRs may alter the properties of the ligand binding sites, but this will be a reflection of what would happen naturally following oligomerization formation and should not be as a result of artificial manipulation.

With regard to the second G-protein, it is preferable that this is rendered non-functional at least with respect to the second GPCR, i.e. such that it cannot act on a signal sent by the GPCR. Thus, in order for the biological reagent to be useful in assays, it is important that the second G-protein is rendered non-functional at least to the extent that it is incapable of activating a cellular signal, i.e. unable to functionally bind GTP and initiate the GPCR signalling cascade.

The present inventor has found that for  $G_{11\alpha}$  G-protein, glycine 208, which is common to these G-proteins, may be mutated, e.g. by substitution, in order to render the G-protein non-functional.

Accordingly, it is preferable to modify the second G-protein by at least one amino acid substitution where

said at least one amino acid is glycine equivalent to glycine 208 in G<sub>11α</sub>.

As mentioned above, it is preferable that the first GPCR  
5 is modified so as to render it non-functional only with  
respect to the G-protein. The field of molecular biology  
has advanced such that it is possible to modify a  
protein's amino acid sequence very specifically so as to  
10 maintain some functions (e.g. ability to bind ligand)  
while disrupting others (e.g. ability to activate G-  
protein). The present inventor has found that the highly  
conserved residues in the 2<sup>nd</sup> intracellular loop of the  
GPCR are particularly suitable for mutation as these  
15 render the receptor substantially non-functional with  
respect to its associated G-protein. Specifically, the  
inventor has found that mutation of one or more residues  
in this region renders the GPCR non-functional with  
respect to G-protein (i.e. G-protein is not activated)  
but still able to bind ligand. Mutations to the GPCR are  
20 discussed in more detail below.

In a second aspect of the present invention, there is  
provided a method of producing a biological reagent  
according to the first aspect, said method comprising the  
25 steps of

(a) producing or providing a first nucleic acid  
construct encoding a fusion protein of a first GPCR and a  
first G-protein wherein the first GPCR is mutated as  
compared to the wild-type such that it is non-functional  
30 with respect to the fused G-protein;

(b) producing or providing a second nucleic acid  
construct encoding a fusion protein of a second GPCR and  
a second G-protein wherein the second G-protein is

mutated as compared to the wild-type rendering it non-functional;

(c) co-expressing the first and second nucleic acid constructs in a cell so as to produce a GPCR oligomer comprising said first and second GPCRs.

If the first and second nucleic acid construct had already been produced, then the method may simply comprise the steps of

(a) expressing a first nucleic acid construct in a cell, said nucleic acid construct encoding a first GPCR/G-protein fusion protein wherein the GPCR is mutated as compared to the native GPCR thereby rendering it non-functional with respect to its G-protein;

(b) expressing a second nucleic acid construct in said cell, said second nucleic acid construct encoding a second GPCR/G-protein fusion protein wherein the G-protein is mutated as compared to the native G-protein thereby rendering it non-functional;

(c) allowing said first and second fusion proteins to assemble into a GPCR oligomer in the cell membrane.

The method may further comprise the step of isolating a part of the cell membrane comprising said complex. This may be achieved by lysing the cell and isolating the cell membrane.

As mentioned above, the first GPCR and the second GPCR may be the same (homo-oligomer) or different (hetero-oligomer).

The present inventor believes that in order for the first and second GPCRs to form an oligomer, they must have some

affinity for each other. Accordingly, the inventor has devised a method by which this may be determined. Thus, as a third aspect of the invention, there is provided a method of determining a first and second GPCR having

5 affinity for each other such that they form a complex (GPCR oligomer), said method comprising the steps of

(a) producing or providing a first nucleic acid construct encoding a first GPCR and its associated G-protein as a fusion protein wherein the GPCR is mutated

10 as compared to the wild-type so that it is non-functional with respect to its associated G-protein;

(b) producing or providing a second nucleic acid construct encoding a second GPCR and its associated G-protein wherein the G-protein is mutated as compared to

15 the wild-type G-protein so that it is non-functional;

(c) co-expressing said first and second nucleic acid constructs in a cell; and

(d) determining the presence of a complex comprising said first and second GPCRs.

20 The presence of a GPCR oligomer comprising said first and second GPCRS may be determined by contacting the cell with a ligand for said second GPCR and determining whether said first G-protein is activated.

25 As before, the first and second GPCRS may be different. Where they are different, it is preferably that they occur naturally on the same cell. This makes it reasonable to predict that the oligomer may be formed in

30 nature. For this reason, the method may further comprise the initial step of determining which GPCRS are present on a particular cell type i.e. which are endogenous to the same cell. As many GPCRS have been fully

characterised, this may be achieved by screening the gene products of a particular cell, e.g. a chip based screen or techniques such as rt-PCR followed by sequencing.

5 The determination of GPCRs that have affinity for each other, i.e. are capable of forming oligomers, is of great importance pharmacologically. For example, the ability of two receptors to form oligomers, (hetero or homo) may be tissue specific. Thus, these tissue specific GPCR  
10 oligomers may form important drug targets. Table 1 indicates an exemplary medical implication which may be associated with each cell type.

The production of biological reagents in accordance with  
15 the present invention, for the first time opens up the possibility of various screening assays which provide convenient and reliable ways to determine the function of the oligomer, particularly with regard to ligand binding and the subsequent cellular signalling cascade.

20 For example, in a fourth aspect of the invention, there is provided a method of detecting an effect a compound has on a GPCR oligomer, comprising the steps of:

a) providing a cell or cell membrane comprising a  
25 biological reagent in accordance with the first aspect of the invention;

b) contacting the compound with said cell or cell membrane; and

c) observing an effect said compound has on the GPCR  
30 oligomer, particularly on the signalling of the GPCR oligomer.

Also in accordance with this aspect of the invention, there is provided a method of identifying a compound capable of interacting with a GPCR oligomer, said method comprising the steps of

- 5           a) producing a cell expressing a GPCR oligomer comprising (i) a first GPCR associated with a first G-protein wherein the first GPCR is non-functional with respect to the associated first G-protein; (ii) a second GPCR associated with a second G-protein wherein the  
10           second G-protein is non-functional;
- b) contacting said cell or isolated cell membrane thereof with said compound;
- c) determining whether said compounds interacts with the GPCR oligomer.

15

It is to be understood that the cell or cell membrane comprising the GPCR oligomer can also comprise non-functional, or a substantially non-functional GPCRs e.g. a monomer comprising either the first or second GPCR (i  
20           or ii), a dimer of the first GPCR (i/i), or a dimer of the second GPCR (ii/ii). The advantage of the present invention is that the formation of these monomers or dimers does not affect the results of the screening method because, owing to the mutations made to the first  
25           and second GPCRs, the only functional receptor (able to stimulate G-protein and initiate a signalling cascade) is the oligomer comprising at least both the first and the second GPCR. Thus, any monomer or homo-oligomer (i.e. both first GPCRs or both second GPCRs) will have no  
30           activity, other than perhaps background activity, compared to the oligomer comprising at least both a first GPCR and a second GPCR.

Background activity is understood to mean less than 20%, 15%, 10% or preferably 5% of native or wild type activity.

5 Interaction of the compound under test with the GPCR oligomer may result in one or more of a number of biological events. For example, interaction may result in a conformational change in the ligand binding site. This may alter the potency of the receptor's natural  
10 ligands. Alternatively, interaction between the compound and the GPCR oligomer may result in a cellular receptor signalling cascade indicating that the compound is a potential agonist. The compound may bind to a ligand binding site present on the native GPCR monomers or it  
15 may bind to a new binding site created as a result of GPCR oligomerization.

A method according to the fourth aspect of the invention may be used to determine new ligands (agonists, antagonists etc) which are able to bind the GPCR  
20 oligomer. It may be that these ligands are different to those able to bind the GPCR oligomer. It may be that these ligands are different to those able to bind and activate the corresponding GPCR monomers, or it may be  
25 that the effect of binding may be different compared to that of the individual monomer. For example, ligand binding to the oligomer, as opposed to the corresponding monomers may result in an altered signal, e.g. increased or decreased, or it may result in a different cellular  
30 pathway being activated. These receptor oligomer properties may all be determined using the method according to the fourth aspect.

Further, the compound under test may have the ability to block a known ligand, e.g. an agonist, of the GPCR oligomer. In order to determine this, the compound may be contacted with the cell in the presence of the known ligand, and the ability of the ligand to activate the GPCR compared to its ability to activate the GPCR in the absence of said compound.

Accordingly, the invention further provides a method of identifying a compound having the ability to modulate binding between a GPCR oligomer and its ligand, said method comprising

a) producing or providing a cell expressing a GPCR oligomer comprising (i) a first GPCR associated with a first G-protein where the first GPCR is non-functional with respect to the associated first G-protein; (ii) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional;

b) contacting said cell with said compound in the presence of said ligand

c) comparing the ability of said ligand to bind GPCR oligomer with the ability of said ligand to bind the GPCR under comparable conditions but in the absence of said compound.

25

Thus, the compound may have the ability to competitively inhibit binding of the ligand to the GPCR or it may in fact result in increased binding and/or increased receptor stimulation as a result of ligand binding, i.e. it increases ligand potency.

30

One possibility is that a third GPCR may complex with the GPCR oligomer and have an allosteric effect. This may be

determined by the above method when the compound is a third GPCR. In this situation, it is preferable that the wild-type third GPCR along with the wild-type first and second GPCRs, are endogenously co-expressed in at least one cell type.

As mentioned above, it is possible that when two GPCRs form an oligomer, their respective ligand binding sites may be altered and/or new ligand binding sites formed. These may have great pharmacological importance. Therefore the present invention further provides, as a fifth aspect, a method for determining the presence of a new or altered ligand binding site on a GPCR oligomer which is not present on the corresponding monomer(s), said method comprising the steps of

a) contacting a compound with a first cell expressing a GPCR complex having (i) a first GPCR associated with a G-protein wherein the first GPCR is modified such that it is non-functional with respect to said G protein; and (ii) a second GPCR associated with a G-protein wherein the G-protein is modified so that it is non-functional;

b) contacting said compound with a second cell expressing an unmodified first GPCR monomer; and

c) comparing the effect of the compound on the first cell and the second cell to determine the presence of a new or altered ligand binding site created by the GPCR oligomer.

Where the GPCR oligomer is a hetero-oligomer, i.e. it comprises at least two different GPCRs, the method may further comprise the step of contacting the compound with a third cell expressing an unmodified second GPCR

monomer, and again, comparing the effect of the compound on the third cell to determine the presence or a new or altered ligand binding site being created as a result of oligomerization of two or more GPCRs.

5

Preferably, the unmodified (i.e. functional) first and second GPCR monomers are expressed in said second or third cell respectively by recombinant means.

10

The presence of a new ligand binding site may be determined by the fact that a particular compound is able to cause a receptor signalling cascade in the cell on contact with the oligomer but not on contact with the corresponding monomer(s).

15

The presence of an altered ligand binding site may be determined by the fact that the receptor signalling cascade is altered as between the oligomer and the corresponding monomer(s), e.g. the signal is increased or decreased, and/or the signalling pathway is altered.

20

The "effect" of the compound on the first or second cell includes its ability to bind to the GPCR oligomer (determined, for example, by labelling the compound) and its ability to initiate a cellular signalling cascade (determined, for example, by detecting changes in the activity of compounds of the signalling pathway).

25

Even if the various ligand binding sites remain unchanged following receptor oligomerization, other changes in receptor function may occur.

30

Accordingly, the present invention further provides a method for determining a change in GPCR function as a result of forming a GPCR oligomer, said method comprising

(a) contacting a compound with a first cell expressing a GPCR oligomer having (i) a first GPCR associated with a G-protein wherein the first GPCR is modified such that it is non-functional with respect to said G-protein; and (ii) a second GPCR associated with a G-protein wherein the G-protein is modified so that it is non-functional;

(b) contacting said compound with a second cell expressing an unmodified first GPCR and/or a second cell expressing an unmodified second GPCR; and

(c) comparing the function of said GPCR oligomer with that of said unmodified first GPCR and/or with that of said second GPCR to determine a change in receptor function resulting from oligomerization.

In the methods described above for determining compounds capable of activating a GPCR oligomer (e.g. in accordance with the fourth aspect) and for determining the presence of a new or altered ligand binding site caused by GPCR oligomerisation (e.g. in accordance with the fifth aspect), the skilled person may choose to add additional mutations to the first and second GPCR to additionally determine changes in ligand binding. The manipulation of the GPCR protein is well within the capabilities of the skilled person. For example, for all aspects of the present invention, it may be possible to additionally modify the GPCR fusion proteins into a constitutively active form. Examples of methods for constitutively activating GPCR sequences are provided in US Patent No. 6,555,339 (incorporated herein by reference) and

PCT/US98/07496, WO 98/46995 (incorporated herein by reference).

5 The biological reagents in accordance with the present invention also allows the determination of differential G-protein coupling as between monomers, homo-oligomers and hetero-oligomers.

10 By way of example, the present invention allows a method to be carried out in order to evaluate if homodimers (e.g. AA or BB) couple to a different G protein than a heterodimer (e.g. AA or BA), comprising the steps of

15 (a) producing or providing a plurality of fusion proteins each comprising one GPCR (e.g. A and B) fused to one of a plurality of different G proteins covering all major G-protein classes (e.g. Gs, Gq and Gi). For example one pair will contain a receptor which is render inactive by mutation in the second intracellular loop which is fused to Gs. The second receptor in this pair  
20 will have a functional receptor fused to a mutated Gs such that the mutation renders the G protein inactive.

The second pair will contain a receptor which is render inactive by mutation in the second intracellular loop which is fused to Gq. The second receptor in this  
25 pair will have a functional receptor fused to a mutated Gq such that the mutation renders the G protein inactive.

The third pair will contain a receptor which is render inactive by mutation in the second intracellular loop which is fused to Gi. The second receptor in this  
30 pair will have a functional receptor fused to a mutated Gi such that the mutation renders the G protein inactive.

Other G proteins such as G12 and G13 may be evaluated in a similar fashion.

(b) producing or providing a control fusion protein for each G protein which has an unmodified fully functional receptor (A or B) and an unmodified fully functional G-protein.

5

Thus, for any one G protein several constructs will be made:

(a) receptor A were the receptor is mutated will be fused to fully functional Gs, Gi and/or Gq

10

(b) receptor B were receptor is functional will be fused to mutated Gs, Gi and/or Gq

(c) receptor A were the receptor is functional will be fused to a mutated Gs, Gi and/or Gq

15

(d) receptor B were the receptor is mutated will be fused to fully functional Gs, Gi and/or Gq

(e) Fully functional fusions of Gs, Gi and Gq will be made for each of receptor A and B.

20

Several cell transfections may be carried out to compare the relative coupling for each. For example, to compare the coupling efficiency of Gs between the homodimer and heterodimer the following will occur:

(a) The first cell will be transfected with a combination of a) and b) above.

25

(b) The second cell will be transfected with a combination of c) and d) above.

(c) The third cell will be transfected with a fully functional fusion of receptor A

30

(d) The fourth will be transfected with a fully functional fusion of receptor B.

The response of each combination will be compared to assess potency of agonists to receptor A and B and

constitutive activity. This process will be repeated for each G protein.

Jürgen Wess (Pharm. Ther. vol. 80, No. 3 1998)  
5 incorporated herein by reference provides information on the molecular basis of receptor/G-protein-coupling selectivity.

#### Brief Description of the Figures

10 Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein  
15 by reference.

**Figure 1** shows a schematic diagram of how it is envisaged reconstitution of function by pairs of mutants occurs. This Figure exemplifies the use of GPCRs fused to a G  
20 protein that typically results in the elevation of intracellular calcium concentrations.

**Figure 2** shows a schematic diagram of how only a oligomer (in this case a dimer) GPCR/G-protein fusion is  
25 functional and homomeric forms are non-functional.

**Figure 3** shows a representation of various class A GPCRs and their associated G-protein(s), as well as residues (highlighted) in the 2<sup>nd</sup> intracellular loop of the GPCR  
30 which are suitable for mutation.

**Figure 4** shows that pairs of distinct non-functional mutants of  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion proteins reconstitute function.

5

A. Membranes of HEK293 cells expressing 40 (I-IV) or 80 (V) fmol of various  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion proteins were used to measure the binding of [<sup>35</sup>S]GTP $\gamma$ S in the absence (open bars) or presence (filled bars) of 10  $\mu$ M phenylephrine. (1) Wild type  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$ , (2)  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>Ala $G_{11}\alpha$ , (3) Leu<sup>151</sup>Asp $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$ , (4 and 5)  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>Ala $G_{11}\alpha$  + Leu<sup>151</sup>Asp $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$ .

10

B. Leu<sup>151</sup>Asp $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  and  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>Ala $G_{11}\alpha$  reconstitute function only when they are co-expressed. The binding of [<sup>35</sup>S]GTP $\gamma$ S in the absence (open bars) or presence (filled bars) of 10  $\mu$ M phenylephrine was measured in HEK293 cell membranes in which Leu<sup>151</sup>Asp $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  and  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>Ala $G_{11}\alpha$  were co-expressed (1) or in which the two constructs were expressed in separate cells populations that were mixed prior to membrane preparation (2) or from which membranes were made separately and then mixed prior to assay (3).

15  
20

25

**Figure 5** shows that pairs of distinct non-functional mutants of histamine H1 receptor- $G_{11}\alpha$  fusion proteins also reconstitute function. Membranes of HEK293 cells expressing 25 (1-4) or 50 (5) fmol of various histamine H1 receptor- $G_{11}\alpha$  fusion proteins were used to measure the binding of [<sup>35</sup>S]GTP $\gamma$ S in the absence (open bars) or presence (filled bars) of 1mM histamine. (1) Wild type histamine H1 receptor- $G_{11}\alpha$ , (2) histamine H1 receptor-

30

Gly<sup>208</sup>AlaG<sub>11</sub>α, (3) Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α, (4 and 5) histamine H1 receptor-Gly<sup>208</sup>AlaG<sub>11</sub>α + Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α.

5 **Figure 6** shows GPCR dimerization and functional reconstitution in single cells. EF88 (mouse embryo fibroblasts derived from an animal in which the genes encoding the calcium mobilising G proteins G<sub>q</sub>α and G<sub>11</sub>α were inactivated) cells were transfected to express GPCR-  
10 G<sub>11</sub>α fusion proteins and GFP and the ability of agonist ligands to elevate intracellular Ca<sup>2+</sup> monitored.

A. EF88 cells were transfected with GFP and histamine H1 receptor-G<sub>11</sub>α (black, n = 6), histamine H1 receptor-Gly<sup>208</sup>AlaG<sub>11</sub>α (blue, n = 10), Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α (green, n = 12) and both histamine H1 receptor-Gly<sup>208</sup>AlaG<sub>11</sub>α and Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α (red, n = 8). The response of GFP positive cells to 1mM histamine was then measured. N = the number of  
15 individual cells quantitated.

B. Only positively transfected cells respond to agonist. Cells were co-transfected with the wild type histamine H1 receptor-G<sub>11</sub>α fusion and GFP. In the field  
25 shown only a single cell expressed GFP (left). Basal (centre) and 1mM histamine (right) stimulated Ca<sup>2+</sup> was then monitored in these cells. Warmer colour represents elevated [Ca<sup>2+</sup>]. Only an increase (warmer colour) in fluorescence was observed in the cell which expressed  
30 GFP.

**Figure 7** shows GPCR dimerisation and functional reconstitution in single cells. Specifically, this

figure shows the ability of two different GPCRs to form an oligomer, i.e. a hetero-oligomer.

A. EF88 cells were transfected to co-express a non-functional form (Leu<sup>133</sup>Asp) of the histamine H1 receptor fused to wild type G<sub>11</sub>α and the wild type form of α<sub>1b</sub>-adrenoceptor fused to the inactive form (Gly<sup>208</sup>Ala) of G<sub>11</sub>α. Both of these GPCR-G protein fusions are inactive when expressed alone because each forms a non-functional homodimer. Co-transfection with GFP allowed detection of positively transfected cells. Addition of phenylephrine (10μM) resulted in an elevation of intracellular calcium concentration but addition of histamine (1mM) resulted in little or no change in calcium concentration. This can only reflect that the occupation of the α<sub>1b</sub>-adrenoceptor by the agonist phenylephrine results in activation of the wild type G<sub>11</sub>α that is physically linked to the inactive histamine H1 receptor and reflects the presence of a functional α<sub>1b</sub>-adrenoceptor-histamine H1 receptor heterodimer.

B. In an analogous fashion EF88 cells were also transfected to co-express a non-functional form (Leu<sup>151</sup>Asp) of the α<sub>1b</sub>-adrenoceptor fused to the wild type G<sub>11</sub>α and the wild type form of the histamine H1 receptor fused to the inactive form (Gly<sup>208</sup>Ala) of G<sub>11</sub>α. In this format addition of phenylephrine (10μM) resulted in little or no change in calcium concentration, whilst addition of histamine (1mM) resulted in elevation of intracellular calcium.

**Figure 8** shows co-immunoprecipitation of differentially epitope tagged forms of both GPCRs and GPCR-G protein

fusions and demonstrates that addition of the G protein to the C-terminal tail of a GPCR does not prevent dimerisation.

5 A.  $\alpha_{1b}$ -adrenoceptor constructs.

B. histamine H1 receptor constructs. HEK293 cells were mock transfected (control) or transfected to express either FLAG, c-myc or a combination (FLAG + myc) of both  
10 epitope tagged forms of the isolated GPCRs or GPCR-G protein fusions. Cells expressing either FLAG or c-myc tagged forms were also mixed (mix). Samples were immunoprecipitated with anti-FLAG antibody, these precipitates resolved by SDS-PAGE and immunoblotted with  
15 anti c-myc antibodies.

**Figure 9** shows that trFRET demonstrates cell surface oligomers of both GPCRs and GPCR-G protein fusions.

A.  $\alpha_{1b}$ -adrenoceptor constructs.

20

B. histamine H1 receptor constructs. HEK293 cells were transfected individually (mix) to express either FLAG or c-myc tagged forms of the isolated GPCRs or GPCR-G protein fusions. These cells were then mixed together.  
25 HEK293 cells were also transfected to co-express FLAG and c-myc epitope tagged forms of the isolated GPCRs or GPCR-G protein fusions (cotransf). Cells were then exposed to Eu3+-labelled anti-c-myc antibodies and allophycocyanin labelled anti-FLAG antibodies (see methods). Energy  
30 transfer was then monitored as described in McVey et al. (2001). Energy transfer is consistent with the FLAG and c-myc tagged polypeptides forming physical complexes (dimers). When expressed in different cells the distance

between the FLAG and c-myc tagged polypeptides is too great to allow effective energy transfer and when in different cells they cannot interact. These experiments thus act as a negative control.

5

**Figure 10** shows that co-expression of pairs of non-functional GPCR-G protein fusions should generate 50% of active dimers. If two distinct GPCRs or GPCR-G protein fusion proteins are co-expressed in a single cell and the affinity of interaction of A with A is the same between A and B then stochastically it must be expected that AA, AB, BA and BB will be present in equimolar amounts. As demonstrated in Figure 2, the methodology developed by the inventors ensures that AA and BB do not respond functionally to addition of ligands for either A or B. However, both AB and BA are potentially functional on addition of ligands for either A or B (see Figures 7C). Thus only 50% of the dimers that form following co-expression of A and B are expected to be functional and these are the combination of each of the differently mutated fusion proteins, e.g. AB or BA.

10

15

20

**Figure 11** shows the  $\alpha_{1b}$ -adrenoceptor and the histamine H1 receptor can form hetero-dimeric complexes.

25

30

A. A FLAG-tagged form of the histamine H1 receptor(flag H1) and a c-myc-tagged form of the  $\alpha_{1b}$ -adrenoceptor (myc  $\alpha_{1b}$  ) were expressed either individually or together (flag + myc) in HEK293 cells. Cells expressing the two constructs individually were also mixed prior to analysis. Samples were immunoprecipitated with anti-FLAG and after SDS-PAGE and transfer, immunoblotted with anti-c-myc-antibodies.

B. Cells either co-expressing FLAG H1 and c-myc  $\alpha_{1b}$  (filled bars) or separate populations of cells expressing either of the two constructs that were then mixed were treated with a combination of  $\text{Eu}^{3+}$ -labelled anti-c-myc and APC-labelled anti-FLAG antibodies were added and tr-FRET measured.

**Figure 12** shows co-expression of an inactive form of the  $\alpha_{1b}$ -adrenoceptor suppresses signalling by a histamine H1 receptor- $G_{11}\alpha$  fusion protein.

HEK293 cells were transfected to express the histamine H1 receptor- $G_{11}\alpha$  fusion protein and with increasing amounts of cDNA encoding the isolated, inactive Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor. (A) Membranes from these cells were used to measure expression of the histamine H1 receptor- $G_{11}\alpha$  fusion protein and amounts containing 25fmol of specific [<sup>3</sup>H]mepyramine binding sites were used to measure basal and 1mM histamine-stimulated [<sup>35</sup>S]GTP $\gamma$ S binding.

(B) EF88 cells were transfected to express the histamine H1 receptor- $G_{11}\alpha$  fusion protein (1) or to co-express this with Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor. The ability of 1mM histamine to elevate cellular [ $\text{Ca}^{2+}$ ]<sub>i</sub> was then assessed. Data represent means +/- S.E.M. n = 6.

**Figure 13** shows provision of excess membrane targeted  $G_{11}\alpha$  does not account for the reconstitution of function in cells expressing pairs of non-functional mutants.

HEK293 cells were transfected to express the c-myc-tagged  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion protein (1),  $G_{11}\alpha$  linked to the C-terminus of a c-myc-tagged form of the N-terminal and first transmembrane region of the  $\alpha_{1b}$ -adrenoceptor

(2), both the  $\alpha_{1b}$ -adrenoceptor and the c-myc-Nt-TM1 $\alpha_{1b}$ -G<sub>11</sub> $\alpha$  construct (3) or c-myc-Nt-TM1 $\alpha_{1b}$ -G<sub>11</sub> $\alpha$  and the  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>AlaG<sub>11</sub> $\alpha$  fusion protein (4). (A) Membrane samples were resolved by SDS-PAGE and  
5 immunoblotted with anti-c-myc antibodies. (B) Basal (open bars) and 10  $\mu$ M phenylephrine stimulation (filled bars) of binding of [<sup>35</sup>S]GTP $\gamma$ S recovered in anti-c-myc immunoprecipitates.

### 10 Detailed Description

Figure 1 shows a representation of how the inventor envisages reconstitution of function by pairs of mutants can occur, thus forming a functional oligomer. As can be seen the functional oligomer is constituted of a first  
15 fusion protein (a) comprising a native GPCR and a mutant G-protein and a second fusion protein (b) comprising a mutant GPCR and a native G-protein. When these two fusion proteins combine functional activation of the GPCR signalling cascade occurs by agonist ligand binding to  
20 the native GPCR of the first fusion protein and functional coupling and signalling through the G-protein of the second fusion protein.

Figure 2 shows how it is envisaged that non-functional homodimers are formed. The non-functional homodimers  
25 comprise either 2 native GPCRs and two mutant G-proteins (a), or two mutant GPCRs and two native G-proteins (b). In either case, the 2 forms of homodimer cannot lead to functional signalling when an appropriate ligand binds to  
30 the GPCR.

The GPCR and associated G-protein

The GPCR and G-protein may be any suitable GPCR/G-protein combination. A non-exclusive list of GPCRs may be found at <http://www.gpcr.org/7tm/>. Preferably the GPCRs and G-proteins are of mammalian origin, more preferably human origin. Typical G protein coupled receptors are for example dopamine receptors, muscarinic cholinergic receptors,  $\alpha$ -adrenergic receptors,  $\beta$ -adrenergic receptors, opiate receptors, cannabinoid receptors, serotonin receptors, somatostatin receptors, adenosine receptors, endothelium receptors, chemokine receptors, melanocortin receptors, neuropeptide Y (NPY) receptors, GnRH receptors, GHRH receptors, TSH receptors, LH receptors, and FSH receptors. Other GPCRs which may be used in accordance with the present invention are described (along with their ligands) in *Trends in Pharmacological Sciences: Ion Channel Nomenclature Supplement* compiled by S. P. H. Alexander & J. A. Peters, 11<sup>th</sup> Edition, Current Trends, London, UK 2000, and *The RBI Handbook of Receptor Classification and Signal Transduction*, K. J. Watling, J. W. Keibabian, J. L. Neumeyer, eds. Research Biomedicals International, Natick, Mass., 1995. Vassilatis et al. PNAS, April 2003, vol.100, 4903-4908. These references are incorporated herein by reference.

It is preferable for all aspects of the present invention that where the first and second GPCR are different, they are endogenously co-expressed by at least one cell type.

GPCRs are presently grouped into 3 main classes - A, B & C. Class A are also called the Rhodopsin-like or rhodopsin family receptors, Class B are the secretin like receptors, Class C the metabotropic receptors. Although

all are GPCRs the three families have no sequence similarities and appear to have been an example of convergent evolution. Examples in Class A include receptors for catecholamines such as adrenaline, histamine, dopamine and serotonin as well as receptors for (neuro) peptides including the opioid peptides, neurokinins, orexins, etc. The olfactory receptors are also part of this group. The Class B receptors total around 65 and the Class C receptors about 18, these include the GABA<sub>B</sub> receptor, the calcium sensing receptor and a family of seven metabotropic glutamate receptors. There are other families of proteins which have yet to be conclusively classed as GPCRs. These include the "frizzled" receptor family and the "Methuselah" receptors.

The G-protein may be any G-protein able to associate/couple with a GPCR. The G-protein preferably has the ability to modulate an intracellular level of Ca<sup>2+</sup>, cAMP, cGMP, inositol 1, 4, 5 triphosphate, diacylglycerol, protein kinase C activity, or MAP kinase activity.

For example, activation of G<sub>i</sub>, G<sub>o</sub>, or G<sub>z</sub> leads to a reduction of the intracellular level of cAMP. Activation of G<sub>q</sub>, G<sub>11</sub>, G<sub>15</sub> or G<sub>16</sub> leads to an increase in the intracellular level of inositol 1, 4, 5 triphosphate and Ca<sup>2+</sup>.

The G-protein may also be selected from the group consisting of G<sub>i</sub>, G<sub>o</sub>, G<sub>z</sub>, G<sub>11</sub>, G<sub>12</sub>, G<sub>13</sub>, G<sub>15</sub>, G<sub>16</sub>, G<sub>s</sub> and G<sub>q</sub>.

In addition to those identified herein, it is well within the expertise of the skilled reader to identify further GPCRs based on sequence information. All GPCRs possess seven highly hydrophobic regions that are long enough (20-25 amino acids) to cross the plasma membrane. Within these some amino acids are substantially always there. For example, in Class A GPCRs there is virtually always a sequence Aspartic acid-Arginine-Tyrosine or something very similar (this is called the DRY domain because of the single letter amino acid code for Aspartic acid (D)-Arginine (R)-Tyrosine (Y). The skilled addressee can also conduct searching with mathematical algorithms such as the "Hidden Markov" method to identify further GPCRs.

Conveniently, the GPCR may be a class A GPCR, examples of which, together with their associated G-protein(s) are shown in Figure 3.

#### Modification of GPCR and G-protein

Figure 3 also shows highly conserved residues in the 2<sup>nd</sup> intracellular loop of the GPCR which are, for example, suitable for mutation and rendering the GPCR substantially non-functional. Mutation of these residues has been shown by the inventor to be particularly efficacious in rendering a GPCR inactive but still capable of binding ligands. Moreover, as the hydrophobic residues are highly conserved, it is envisaged that all class A GPCR can be mutated in this manner to render them inactive. Typically the residue is a hydrophobic one, which may be mutated to an acidic residue by for example site-directed mutagenesis techniques known in the art. However, any other mutation which renders the GPCR functionally inactive or substantially functionally

inactive may be carried out and their activities/lack of activity tested using the assays described herein-after in relation to assaying heterodimer activity. That is, a functional assay for a native GPCR may be carried out on a mutagenised GPCR in order to ascertain what degree of activity remains after mutagenisation. If a first round of mutagenesis is not sufficient to render a GPCR inactive, a further round of mutagenesis may be carried out and activity tested thereafter.

10

It is also possible to conduct random mutagenesis or applied molecular evolution and then test the activity of the mutants. Moreover crystal structures of G proteins are known and important residues identified therefrom, so that targeted mutagenesis can be carried out.

15

A publicly available web site

(<http://www.cbs.dtu.dk/services/TMHMM/>) may be used by the skilled person to identify transmembrane domains with the GPCR structure. This allows site directed mutagenesis to be carried out in order to determine mutants which render the GPCR inactive but still able to bind ligand. The 2nd intracellular loop (IC2) would be defined as the polypeptide segment between transmembrane (TM)3 and TM4. This site would at least provide guidance with respect to identifying the neighbourhood of a GPCR amino acid sequence that one would want to align with the IC2 sequences in Fig. 3 for the purpose of making an analogous mutation(s).

25  
30

The membrane GPCRs mentioned herein are typically modified by the fusion of an associated G-protein to the receptor. Typically nucleic acid encoding the G-protein

may be fused in-frame to the 3' end, of a gene encoding the particular GPCR from which the stop codon has been eliminated. In this manner, on expression of the nucleic acid, the reporter protein is functionally expressed and fused to the C-terminal end of the GPCR. Modification of the receptor is such that the functionality of the membrane receptor remains substantially unaffected by fusion of the G-protein to the receptor.

The mutation which can be carried out to the G-protein, may be any suitable mutation which renders the G-protein non-functional (ie. unable to functionally bind GTP and initiate the GPCR signalling cascade). Again, this can easily be tested by the skilled addressee using the assays described herein. One suitable mutation which may be made is mutation of the glycine at position 208 of  $G_{11\alpha}$  to, for example alanine. All G-proteins possess the glycine at position 208, or equivalent site/residue and so an equivalent mutation is envisaged to render other G-proteins inactivate. Other suitable mutations can easily be identified as those which effect the sequences that allow proteins to bind and hydrolyse GTP. To date G-protein sequences have been observed as being highly conserved through evolution and the sequences identified as being involved in allowing proteins to bind and hydrolyse GTP are highly conserved.

It is therefore a relatively straightforward task to be able to couple any receptor (native or mutant) to an appropriate G-protein (native or mutant).

Constitutively Active GPCRs and Functional Genomics

Perhaps the most challenging step in drug development today relates to target validation. The large public, and private, human genome sequencing efforts which have come to fruition in recent years have provided unprecedented numbers of gene targets for pharmaceutical development. Deciphering the functionality and, most importantly, potential therapeutic relevance of these gene targets is of high priority as the basis for the development of next-generation therapeutics. This challenge is of no greater magnitude than within the GPCR gene family where large numbers of novel genes have been identified. Having identified GPCRs exhibiting high or selective expression within tissues of interest it is possible to further refine the analysis to the cellular level. This may involve using both RNA probes and antibodies to map the cellular populations within tissues which express any GPCRs of interest.

For orphan GPCRs with no identified ligand, constitutively active forms of the receptor may then be employed as a tool to further investigate their functional roles. Such an approach, in essence, simulates the effect of ligand stimulation on the target GPCR. For example, orphan GPCRs have been identified which are selectively expressed within pancreatic B cells as a means to identify potential targets to regulate insulin secretion. Examination of the constitutively active form of one such receptor, "islet receptor 1", in *in vitro* systems confirms that the receptor couples to the appropriate cellular signaling molecules (adenylate cyclase) to regulate insulin release. Furthermore, utilization of this constitutively active receptor in an insulin producing cell line confirms that the active form

of the receptor enhances glucose-sensitive insulin release. These data provide highly suggestive information supporting the development of "islet 1" GPCR agonists as a means to regulate insulin release.

5

In order to examine GPCR expression comprehensively, an oligonucleotide GPCR chip has been synthesised by Arena Pharmaceuticals Inc., 6166 Nancy Ridge Drive, San Diego, CA 92121, USA., containing all available human GPCR sequences, as well as markers for cellular function and disease state. This approach allows rapid identification of gene expression profiles for GPCRs across a wide variety of human tissues on a macro scale. Cluster analysis can also be applied to identify tissue-specific patterns of gene expression which may indicate functional roles. Assessment of the tissue distribution of GPCRs and related signaling molecules may therefore clarify the complexity of the molecular mechanisms by which receptor signaling transduce extracellular stimuli. The sequencing of the human genome has brought new avenues by which global approaches can be undertaken to investigate the breadth of GPCR signaling. It is now estimated that the GPCR superfamily consists of 600-1000 receptors. The advent of microarray technology allows for a large sampling of the receptor family to be performed. This technology permits one to monitor the message levels of thousands of genes simultaneously in a given sample. Evaluation of the transcriptional levels for these genes across a large panel of tissues would thus provide a global view of GPCR signaling in the human body.

10

15

20

25

30

Cells Suitable for Expression of Modified GPCR and G-protein

A variety of cells may be used to express nucleic acid constructs encoding the fusion proteins of the present invention. All cells that can be transfected to express the modified GPCRs are considered to be within the scope of the invention. Examples of such cells include neonatal cells, endocrine cells, tumour cells, acinar cells, islet cells, immune cells, neuroendocrine cells, neuronal cells, and pituitary cells. It is also well within the capabilities of the skilled person to determine other cell lines which are able to express the modified GPCRs in accordance with the invention, e.g. CHO (Chinese hamster ovary) cells (CHO-K1) and HEK (human embryonic kidney) cells.

In carrying out the assays of the present invention, it may be preferable to use cell lines which do not express any endogenous GPCRs to high levels. CHO-K1 is an example of such a cell line.

Certain cells may be chosen to express the GPCR oligomers of the present invention owing to their ability to react to GPCR signalling cascade. For example, in assays for determining a ligand for a GPCR oligomer, it may be convenient to express the GPCR in a cell which has a detectable change in characteristic upon receptor activation, e.g. pigment cells. US 5,462,856 (incorporated herein by reference) describes methods of developing rapid and sensitive bioassays for evaluating new agonists and antagonists for GPCRs using pigment cell lines. Assays for determining GPCR activity are discussed in more detail below. Accordingly, pigment cells which may be transfected with nucleic acid constructs according to the present invention include

chromatophores, melanophores or melanocytes, xanthophores, erythrophores, leukophores and iridophores. Such cells may conveniently be obtained from lower animals such as Reptilia, e.g. *Anolis* sp: Amphibia, e.g., *Xenopus laevis*; *Pieces*, e.g., *Zacco temmincki*; Crustacia, e.g., *Uca pugilator*; Echinodermata, e.g., *Diadema antillarum* and *Cnidaria*, e.g., *Nanomsa cara*. Particularly preferred pigment cells for use in the present invention are cultured melanophores from the *Xenopus laevis* (Pigment Cell 1985), ed. Bagnara et al., University of Tokyo Press, pages 219-227) and Lerner et al. (1988) *P.N.A.S. USA*, 85: 261-264.

Using nucleic acid constructs to transfect a cell is well within the capabilities of the person skilled in the art. Standard methods include lipofectamine, calcium phosphate precipitation, electroporation, gene guns, liposomes and viral vectors.

An expression vector e.g. plasmids, viral vector etc. is a replicable DNA construct in which the nucleic acid is operably linked to suitable control sequences capable of effecting the expression of the membrane receptor/reporter fusion in the particular cell. Typically control sequences may include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and/or translation. Typically expression vectors may include for example plasmids, bacteriophages or viruses and such vectors may integrate into the host's genome or replicate autonomously in the particular cell.

A variety of expression vectors are available to the skilled person. A preferred vector is pCMV which is deposited at ATCC under deposit number ATCC#203351.

5

In order for the particular cell to express the mutant GPCR/G-protein fusion proteins the cell must be transformed by the appropriate expression vector. "Transformation", as used herein, refers to the introduction of a heterologous polynucleotide fragment into a host cell, irrespective of the method used, for example direct uptake, transfection or transduction.

10

The present invention therefore also relates to cells which have been transformed by nucleic acid constructs comprising mutant GPCR/G-protein fusions of the present invention and which express the mutant GPCR/G-protein fusion proteins. In the methods of the present invention, the cells may be lysed prior to use, such that only the cell membranes, in which the GPCR is located, may be used.

15

20

#### Assays for Determining GPCR Activity

Having co-transfected a cell with nucleic acid constructs encoding the modified GPCRs, it may then be evaluated for binding of at least one ligand specific for at least the functional (second) GPCR. The functional activity of a GPCR oligomer in accordance with the present invention may be determine by a number of standard and well known techniques. GPCRs are known to affect adenylyl cyclase activity, to modulate the conductance of voltage-gated calcium channels, to modulate potassium channels, to activate the MAP kinase pathway, to activate the

25

30

phospholipase C (PLC)-IP<sub>3</sub> pathway, to activate phosphotyrosine phosphatase, to stimulate mitogenesis, to stimulate exocytosis, to stimulate cytostasis, to stimulate chemotaxis and to induce apoptosis. These activities may be measured by the skilled person using routine and standard methods. The functional activity may also be determined using these techniques in assays for determining a ligand of the GPCR (see below).

Observing the effect said compound has on the functioning of the GPCR heterodimer may be carried out by assaying for a level of a down-stream component of said GPCR signalling cascade. One convenient component to detect is a level/change in level of calcium. Typically as calcium ions. As an alternative to calcium detection, it is also possible to utilise analogues of GTP, which bind to the active G protein, as detection agents and also reporter gene assays known to those skilled in the art.

The level of cytosolic calcium within the normal and abnormal cells may be detected by methods known to the skilled addressee that monitor cytosolic calcium levels. Indicator dyes may be used, for example fluorescent probes (such as fura-2, fluo-3 or -4, indo-1, quin-2) show a spectral response upon binding calcium and it is then possible to detect changes in intracellular free calcium concentrations using for example fluorescence microscopy, flow cytometry and fluorescence spectroscopy. Most of the above fluorescent indicators are variations of the nonfluorescent calcium chelators EGTA and BAPTA. Other examples are obtainable from, for example, Molecular Probes, Oregon, USA.

Additionally, the present methods are particularly suited to the development of high-throughput screens where detection may be carried out using for example a CCD camera, a luminometer, or any other suitable light  
5 detection system. In this manner, cells/cell membranes may be provided for example in multi-well plates to which test substances and reagents necessary for the detection of intracellular calcium may be added. Moreover, commercially available instruments such as "FLIPR-  
10 flumetric imaging based plate reader" (Molecular Devices Corp, Sunnyvale, CA, USA) may be used. New fluorescent indicators for calcium called "chameleons" may also be used and are genetically encoded without cofactors and are targetable to specific intracellular locations.  
15 These so-called "chameleons" consist of tandem fusions of a blue-or cyan-emitting mutant of the green fluorescent protein (GFP), calmodulin, the calmodulin-binding peptide M13, and an enhanced green- or yellow-emitting GFP. Binding of calcium makes calmodulin wrap around to M13  
20 domain, increasing (Miyawaki et al 1997) or decreasing (Romoser et al 1997) the fluorescence resonance energy transfer between flanking GFPs.

Another method for intracellular calcium concentration  
25 measurement is the use of cell lines overexpressing a GPCR and apoaequorin, such as described by Sheu et al. (1993). In this system, cells expressing apoaequorin are incubated with coelenterazine, which is the co-factor of aequorin. During this incubation, coelenterazine enters  
30 the cell and conjugates with apoaequorin to form aequorin, which is the active form of the enzyme. Upon incubation of the cells with an agonist of the GPCR, intracellular calcium concentration increases. This

increase leads to the activation of the catalytic activity of aequorin, which oxidises coelenterazine and yields apoaequorin, coelenteramide, CO<sub>2</sub> and light. Once the photon has been emitted, the complex must dissociate and apoaequorin must recombine with a new coelenterazine molecule to be able to emit light again. Thus, in this system, measurement of light emission following agonist addition reflects its ability to activate the GPCR and thus to increase intracellular calcium concentration.

10

Other suitable detection mechanisms include detection of other second messengers apart from CA<sup>2+</sup> eg. cAMP levels, cGMP levels, inositol 1, 4, 5 triphosphate levels, diacylglycerol levels, protein kinase C activity or MAP kinase activity). It is also possible to use reporter genes because activation of GPCRs generally results in changes in gene expression over time (this can be done with reporters coupled to promoter elements that respond to changes in cAMP levels or activation of kinases). A further method utilises melanocytes as described for example in US5,462,856 (incorporated herein by reference) and US6,051,386 (incorporated herein by reference), which describe methods in which signals generated by functional activation of a GPCR alter the aggregation state of pigment in the cells and the cell either appear more or less opaque due to the pigmentation, which is easily detected by, for example, colourimetric means. The alteration of the aggregation state may result in increased aggregation or conversely a decrease in aggregation (dispersion).

30

### Reporter Assays

The signaling from GPCR oligomers can also be assessed using a variety of reporter systems. To measure changes in intracellular cAMP levels a reporter construct driven by a promoter containing cyclic AMP response elements (CRE) would be preferable. To measure responses driven from a Gq pathway that lead to activation of protein kinase C a PKC-sensitive reporter system would be preferable that contained AP1 sites in its promoter sequence. Other reporters sensitive to MAP kinase activation and reporters containing serum response elements (SREs) could also be use to measure responses from the GPCR oligomers. The reporter molecules themselves can range and examples of these include, luciferase, beta-galactosidase, beta-lactamase, green fluorescent protein, yellow fluorescent protein and others.

### Determination of Ligand Binding

The present invention is particularly suited for determining new ligands which bind to a GPCR as a result of oligomerization. Naturally occurring and synthetic ligands well known to the skilled person may be tested. Suitable test ligands may come from combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries which may be screened for activity. In one possible approach the candidate substances may for example be used in an initial screen in batches, for example 10 substances per reaction, and the substances of those batches which show an effect tested individually.

Typically the assay may be used to screen compounds for their effect on particular membrane GPCRs. Compounds identified as having an effect on a particular membrane receptor may be useful, for example, in modulating the activity of wild type and/or mutant membrane receptors; 5 may be used in elaborating the biological function of particular membrane receptors; and/or may be used in screens for identifying compounds that disrupt normal membrane receptor interactions, or can in themselves 10 disrupt such interactions.

The assay is particularly suited for the detection of compounds which serve as inverse agonists, antagonists or agonists of the membrane receptor. The term inverse 15 agonist is understood to mean a compound which when it binds to a receptor, selectively stabilises and thus enriches the proportion of a receptor in a conformation or conformations incapable of inducing a downstream signal. Agonist is understood to mean a compound which 20 when it binds to a receptor selectively stabilises and thus enriches the proportion of the receptor in a conformation or conformations capable of inducing a downstream signal. Antagonist is understood to mean a compound which when it binds to a receptor has no 25 selective ability to enrich either active or inactive conformations and thus does not alter the equilibrium between them.

The present invention also therefore relates to inverse 30 agonists, antagonists or agonists of receptor proteins identified using the assays according to the present invention and to the use of such agonists, antagonists or

agonists in studying dimer or oligomer GPCR function, or therapy.

5 The following provides specific examples for working the present invention, and outlines the work carried out by the inventor resulting in the present invention.

#### Materials and Methods

10 A fibroblast cell line (EF88) (Gohla et al, 1999) derived from a combined  $G\alpha_q/G\alpha_{11}$  double knockout mouse (Offermans, et al, 1998) was the gift of Dr. M.I. Simon, California Institute of Technology, Pasadena CA. All materials for tissue culture were supplied by Life Technologies Inc. (Paisley, Strathclyde, UK). [ $^3\text{H}$ ]prazosin (80 Ci/mmol), 15 [ $^3\text{H}$ ]mepyramine (30 Ci/mmol) and [ $^{35}\text{S}$ ]GTP $\gamma$ S (1250 Ci/mmol) were from NEN/Perkin Elmer. Oligonucleotides were purchased from Cruachem (Glasgow, Strathclyde, UK). Reagents for time-resolved fluorescence resonance energy transfer were from Wallac. Receptor ligands were 20 purchased from RBI (Gillingham, Kent, U.K. Production and characterization of the anti- $G_q/G_{11}$  antiserum CQ was described by (Mitchell et al, 1991; Mitchell et al, 1993). Widespread distribution of  $G_q/G_{11}\alpha$  detected immunologically by an antipeptide antiserum directed 25 against the predicted C-terminal decapeptide. FEBS Lett. 287, 171-174.

All other chemicals were from Sigma (Poole, Dorset, U.K.) and were of the highest grade available.

30

#### Construction of fusion proteins

Production and subcloning of wild type and mutated  $\alpha_{1b}$ -adrenoceptor- $G\alpha_{11}$  fusion proteins was performed as

described in (Carrillo, et al., 2002). Production and subcloning of the human histamine H<sub>1</sub> receptor-G<sub>11</sub>α fusion proteins was performed in two separate stages. In the first step, using the amino-terminal primer 5'-  
5 GATACTGGGCTATCCAAGCTTATGAGCCTCCCAATTCCTC-3', a *Hind*III restriction site (underlined) was introduced by PCR upstream of the coding sequence of the human histamine H<sub>1</sub> receptor. Using a carboxyl-terminal primer 5'-  
10 AAGGAAAAAAGCGGCCGCTGGAGCGAATATGCAGAATTCTCT -3' a three amino acid spacer (Ser-Gly-Arg) and a *Not*I restriction site were introduced immediately upstream of the stop codon. Similarly, the mouse G<sub>11</sub>α sequence was amplified by PCR using the amino-terminal primer 5'-  
15 AAGGAAAAAAGCGGCCGCGCATGACTCTGGAGTCCATGATGGC-3' and the carboxyl-terminal primer 5'-  
ATGAAACCGCTCGAGTCACACCAGGTTGTACTCCTTCAG-3'. This introduced *Not*I and *Xho*I restriction sites flanking the G<sub>11</sub>α coding sequence respectively. In the second step, the amplified receptor fragment was digested with  
20 *Hind*III/*Not*I and the G<sub>11</sub>α fragment digested with *Not*I/*Xho*I. These fragments were purified and ligated into pcDNA 3 vector (Invitrogen) previously digested with *Hind*III/*Xho*I. The choice of intracellular loop 2 Leu to Asp mutants was based on the studies of Greasley et al.,  
25 2001. In the vast majority of class A GPCRs the equivalent position is also a hydrophobic amino acid (see Figure 2). Such mutations were introduced into the fusion protein constructs using PCR mutagenesis by standard methods of site directed mutagenesis (Sambrook et al. and Carrillo et al., Manufacturers Kit etc.).  
30

For co-immunoprecipitation and trFRET studies, c-myc (EQKLISEEDL) or FLAG (DYKDDDDK) epitopes were introduced

immediately after the NH<sub>2</sub>-terminal methionine. Each construct was fully sequenced before its expression and analysis (Mitchell et al., 1991; Mitchell et al., 1993).

5 Transient transfection of HEK293 cells

HEK293 cells were maintained in DMEM supplemented with 0.292 g/liter L-glutamine and 10% (v/v) newborn calf serum at 37°C in a 5% CO<sub>2</sub> humidified atmosphere. Cells were grown to 60-80% confluency before transient  
10 transfection in 60 mm dishes. Transfection was performed using LipofectAMINE reagent (Life Technologies, Inc.) according to the manufacturer's instructions.

[<sup>35</sup>S]GTPγS binding

15 [<sup>35</sup>S]GTPγS binding experiments were initiated by the addition of membranes containing defined amounts of the fusion constructs (see Results for details) to an assay buffer (20 mM HEPES (pH 7.4), 3 mM MgCl<sub>2</sub>, 100 mM NaCl, 1 μM guanosine 5'-diphosphate, 0.2 mM ascorbic acid, 50 nCi  
20 [<sup>35</sup>S]GTPγS) containing the indicated concentrations of receptor ligands. Non-specific binding was determined in the same conditions but in the presence of 100 μM GTPγS. Reactions were incubated for 15 min at 30°C and were terminated by the addition of 0.5 ml of ice cold buffer,  
25 containing 20 mM HEPES (pH 7.4), 3 mM MgCl<sub>2</sub> and 100 mM NaCl. The samples were centrifuged at 16,000g for 15 min at 4°C, and the resulting pellets were resuspended in solubilization buffer (100 mM Tris, 200 mM NaCl, 1 mM EDTA, 1.25% Nonidet P-40) plus 0.2% sodium  
30 dodecylsulfate. Samples were precleared with Pansorbin (Calbiochem), followed by immunoprecipitation with CQ antiserum (Mitchell et al., 1993).

Finally, the immunocomplexes were washed twice with solubilization buffer, and bound [<sup>35</sup>S]GTPγS measured by liquid-scintillation spectrometry.

5 [<sup>3</sup>H]ligand binding studies

[<sup>3</sup>H]prazosin binding studies, to monitor expression of the α<sub>1b</sub>-adrenoceptor containing constructs, were performed as in (Carillo, et al., 2002). [<sup>3</sup>H]mepyramine binding assays, to monitor expression of the histamine H1  
10 receptor containing constructs were initiated by the addition of 3 μg of cell membranes to an assay buffer (50 mM Tris-HCl, 100 mM NaCl, 3 mM MgCl<sub>2</sub>, pH 7.4) containing [<sup>3</sup>H]mepyramine (0.1-10 nM). Non-specific binding was determined in the presence of 100 μM mepyramine.  
15 Reactions were incubated for 30 min at 25°C, and bound ligand separated from free by vacuum filtration through GF/B filters. The filters were washed twice with assay buffer, and bound ligand estimated by liquid scintillation spectrometry.

20

[Ca<sup>2+</sup>]<sub>i</sub> imaging

EF88 cells were grown in DMEM supplemented with 10% (v/v) heat inactivated foetal bovine serum and L-glutamine (1 mM) in a 95% air and 5% CO<sub>2</sub> atmosphere at 37°C. A  
25 portion of the cells harvested during trypsinization were plated on to glass coverslips and after a 24 h growth period they were transfected using LipofectAMINE (Life Technologies Inc.) according to the manufacturers' instructions. After 3 h cells were washed twice with  
30 OPTIMEM 1 and then cultured in DMEM growth medium for a further 24 h. A total of 3 μg of pCDNA3 containing the relevant cDNA species were used to transfect each coverslip. Transfected EF88 cells were loaded with the

Ca<sup>2+</sup>-sensitive dye Fura-2 by incubation (15-20 min, 37°C) under reduced light in DMEM growth medium containing the dye's membrane-permeant acetoxymethylester form (1.5 μM). Details of imaging studies and their analysis is described in Liu et al., 2002.

#### GPCR co-immunoprecipitation studies

Co-immunoprecipitation studies using FLAG and c-myc tagged forms of the α<sub>1b</sub>-adrenoceptor and histamine H1 receptor constructs were performed as in (McVey et al., 2001). In the studies with the histamine H1 receptor 30U/ml of endoglycosidase F were added.

#### Time resolved fluorescence resonance energy transfer

Was performed on intact HEK293 cells using Eu<sup>3+</sup>-labelled anti-c-myc antibodies and allophycocyanin-labelled anti-FLAG antibodies as described in (McVey et al., 2001).

#### Results

The present inventor has previously generated a fusion protein between the α<sub>1b</sub>-adrenoceptor and the α subunit of G<sub>11</sub> that binds both agonists and antagonist ligands including [<sup>3</sup>H]prazosin (Carillo, et al., 2002). Addition of the agonist phenylephrine to membranes of HEK293 cells transfected to express this construct resulted in a large stimulation of the binding of [<sup>35</sup>S]GTPγS monitored following end of assay immunoprecipitation using an antiserum against the C-terminal decapeptide of G<sub>11</sub>α (Fig 4A).

30

Introduction of a Gly<sup>208</sup>AlaG<sub>11</sub>α mutant into the fusion protein essentially eliminated phenylephrine stimulation of [<sup>35</sup>S]GTPγS binding when membranes expressing equal

amounts of this construct were used (Figure 4A(2)) because this form of the G protein is unable to release bound GDP. However, this mutation did not alter the binding properties of either [<sup>3</sup>H]prazosin or phenylephrine).

5

Previous studies have shown that mutation of hydrophobic amino acids in intracellular loop 2 of the  $\alpha_{1b}$ -adrenoceptor can eliminate agonist-mediated signal transduction (Greasley et al., 2001). The present inventor thus generated a fusion protein between Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor and G<sub>11</sub> $\alpha$ . This bound both [<sup>3</sup>H]prazosin and phenylephrine as the wild type fusion protein (not shown) but phenylephrine was again unable to stimulate binding of [<sup>35</sup>S]GTP $\gamma$ S (Figure 4A(3)). However, co-expression of the two non-functional mutants reconstituted phenylephrine-mediated binding of [<sup>35</sup>S]GTP $\gamma$ S (Figure 4A(4)) and when the membrane amounts employed contained twice as many [<sup>3</sup>H]prazosin binding sites as used for each individual construct the level of agonist-mediated [<sup>35</sup>S]GTP $\gamma$ S was almost as high as when employing the wild type fusion construct (Figure 4A(5)).

10

15

20

25

30

Reconstitution of function required co-expression of the two mutant fusions. If the two constructs were expressed in separate cell populations and either the cells mixed prior to membrane preparation or membranes prepared individually and then combined prior to assay, no agonist-stimulated binding of [<sup>35</sup>S]GTP $\gamma$ S was observed (Figure 4B). Such results are consistent with the hypothesis that GPCR dimerization is required for agonist function. Furthermore, within the dimer, one GPCR element activates the G protein physically linked to the partner GPCR.

To extend this basic concept an equivalent set of experiments was performed using fusions between the histamine H1 receptor and  $G_{11}\alpha$ . The basic results were the same. The fusion containing wild type forms of both the GPCR and G protein produced a large stimulation of [ $^{35}$ S]GTP $\gamma$ S binding in the presence of histamine (Figure 5(1)). This was absent upon separate expression of either a histamine H1 receptor-Gly $^{208}$ Ala  $G_{11}\alpha$  fusion protein (Figure 5(2)) or a fusion between Leu $^{133}$ Asp histamine H1 receptor and wild type  $G_{11}\alpha$  (Figure 5(3)). Co-expression of these two mutants again reconstituted agonist activation of the G protein (Figure 5(4)). Again, following co-expression of the two mutants, membranes expressing a 2 fold higher number of [ $^3$ H]antagonist binding sites produced as high a level of [ $^{35}$ S]GTP $\gamma$ S binding upon addition of the agonist histamine as the wild type histamine H1 receptor- $G_{11}\alpha$  fusion protein expressed in isolation (Figure 5(5)).

As an extension to these studies the present inventors attempted to monitor functional reconstitution and dimerization in a single cell. To do so they employed  $Ca^{2+}$  imaging using EF88 cells. EF88 cells are a line of mouse embryo fibroblasts that are derived from a  $G_q\alpha/G_{11}\alpha$  double knock-out mouse (Mao et al., 1998; Yu and Hinkle, 1999). They thus require expression of both a functional GPCR and functional  $Ca^{2+}$ -mobilizing G protein to produce elevation of intracellular [ $Ca^{2+}$ ] (Liu et al., 2002; Stevens et al., 2001). Upon introduction of fusions between wild type forms of either the histamine H1 receptor or the  $\alpha_{1b}$ -adrenoceptor and  $G_{11}\alpha$  agonists produced elevation of intracellular [ $Ca^{2+}$ ] (Figure 6).

This occurred only in positively transfected cells. As EF88 cells are recalcitrant to transfection the present inventors co-transfected with enhanced green fluorescent protein (GFP) to allow visualization of the positively transfected cells. Only those cells that were positive for GFP responded to agonist ligands (Figures 6b). For both the histamine H1 receptor and the  $\alpha_{1b}$ -adrenoceptor the fusions containing either the non agonist-responsive GPCR or the G protein mutant failed to elevate intracellular  $[Ca^{2+}]$ . However, co-expression of the pairs of non-functional fusions again resulted in effective signal generation (Figures 6a, 6b, 7a and 7b).

The present inventor has also demonstrated directly the ability of both the isolated GPCRs and the GPCR/G protein fusions to form dimers/oligomers. Constructs were N-terminally epitope tagged with either the c-myc or FLAG tags. Following co-expression in HEK293 cells of both tagged forms of the  $\alpha_{1b}$ -adrenoceptor, but not their separate expression followed by cell mixing, immunoprecipitation with anti-FLAG antibodies resulted in the presence of anti-c-myc immunoreactivity in the precipitate (Figure 8a). SDS-PAGE demonstrated the presence of bands identified by the c-myc antibody of apparent size 53kDa and 110kDa that would be consistent with monomeric and dimeric forms of the  $\alpha_{1b}$ -adrenoceptor. Anti c-myc immunoreactivity was also observed near the top of the gel and this may represent either a higher-order oligomer or aggregated protein (Figure 8a). When equivalent experiments were performed with the  $\alpha_{1b}$ -adrenoceptor- $G_{11\alpha}$  fusion protein similar results were obtained except that the anti-c-myc reactive bands were now of apparent mass 90kDa and 200kDa, consistent with

the anticipated size of monomeric and dimeric forms of this fusion protein (Figure 8A). Similar results were obtained for FLAG and c-myc tagged forms of the histamine H1 receptor (Figure 8B). The monomeric form of the isolated receptor migrated as an approximately 50kDa polypeptide with the dimeric form migrating as anticipated for a polypeptide of some 100kDa (Figure 8B). Again, as with the  $\alpha_{1b}$ -adrenoceptor, a series of higher molecular mass species were also detected. When using the histamine H1 receptor- $G_{11}\alpha$  fusion protein both the monomeric and dimeric species were also easily detected (Figure 8b).

A series of issues have been raised about the meaning and validity of GPCR dimerization data that rely exclusively on co-immunoprecipitation (Milligan G, 2001; Salim et al., 2002). The present inventors thus monitored dimerization/oligomerization of both the isolated  $\alpha_{1b}$ -adrenoceptor and the  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion protein in intact HEK293 cells using time-resolved fluorescence resonance energy transfer (tr-FRET). When co-expressing c-myc and FLAG-tagged forms of either the isolated GPCR or the fusion protein a clear energy transfer signal was obtained upon addition of a combination of  $\text{Eu}^{3+}$ -labelled anti-c-myc antibodies, as energy donor and allophycocyanin (APC)-labelled anti-FLAG antibodies as energy acceptor (Figure 9A). An energy transfer signal was not obtained when the tagged forms of the GPCR constructs were expressed in separate population of cells that were mixed prior to the addition of the antibodies. Equivalent results were obtained in HEK293 cells expressing N-terminally c-myc and FLAG-tagged forms of

both the histamine H1 receptor and the histamine H1 receptor- $G_{11}\alpha$  fusion protein (Figure 9B).

To examine the possibility of hetero-dimerisation between  
5 the histamine H1 receptor and the  $\alpha_{1b}$ -adrenoceptor and the  
mechanism of G protein activation by GPCR dimers the  
inventor co-expressed a FLAG-tagged form of the histamine  
H1 receptor and the c-myc-tagged form of the  $\alpha_{1b}$ -  
adrenoceptor. Following immunoprecipitation with anti-  
10 FLAG antibodies and SDS-PAGE, c-myc immunoreactivity was  
detected in polypeptides of apparent molecular mass 50  
and 100 kDa consistent with the immunoprecipitation of  
histamine H1 receptor- $\alpha_{1b}$ -adrenoceptor hetero-dimers that  
are only partially separated by the electrophoresis  
15 conditions employed (Figure 11A). tr-FRET studies  
following co-expression of the FLAG-tagged form of the  
histamine H1 receptor and the c-myc-tagged form of the  
 $\alpha_{1b}$ -adrenoceptor confirmed the presence of histamine H1  
receptor/ $\alpha_{1b}$ -adrenoceptor hetero-dimers at the cell  
20 surface (Figure 11B) although the absolute level of the  
signal indicated that these hetero-dimers formed less  
efficiently than the corresponding homo-dimer pairs (see  
y-axis of Figures 9A and 9B compared to Figure 11B). As  
in the homo-dimer studies no tr-FRET signal was observed

when separate cell populations expressing each of these receptors were mixed prior to analysis (Figure 11B).

When Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α was co-expressed  
5 in EF88 cells with α<sub>1b</sub>-adrenoceptor-Gly<sup>208</sup>Ala G<sub>11</sub>α,  
phenylephrine was able to elevate intracellular [Ca<sup>2+</sup>] but  
histamine was not (Figure 12A). This can only occur if  
the α<sub>1b</sub>-adrenoceptor activates the G protein physically  
linked to the Leu<sup>133</sup>Asp histamine H1 receptor. When the  
10 protocol was reversed by co-expression of Leu<sup>151</sup>Aspα<sub>1b</sub>-  
adrenoceptor-G<sub>11</sub>α and histamine H1 receptor-Gly<sup>208</sup>Ala G<sub>11</sub>α  
histamine now caused elevation of intracellular [Ca<sup>2+</sup>] but  
phenylephrine did not (Figure 7B). To extend this type  
of analysis the histamine H1 receptor-G<sub>11</sub>α fusion was co-  
15 expressed with the isolated Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor that  
is unable to activate G protein and thus stimulate  
binding of [<sup>35</sup>S]GTPγS. Histamine stimulation of [<sup>35</sup>S]GTPγS  
binding was significantly reduced in comparison to  
membranes expressing the same level of only the histamine  
20 H1 receptor-G<sub>11</sub>α fusion (Figure 12A). Such data are  
consistent with the Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor generating  
inactive hetero-dimers with histamine H1 receptor-G<sub>11</sub>α and  
indicate that the histamine H1 receptor in the hetero-  
dimer does not activate the G protein physically

associated with it. The remaining signal produced by histamine in the co-transfection reflects that some functional histamine H1 receptor-G<sub>11</sub>α homo-dimer is still formed in the presence of Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor.

5 Indeed, when the inventor co-expressed histamine H1 receptor-G<sub>11</sub>α with increasing amounts of Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor cDNA, the ability of histamine to cause [3<sup>5</sup>S]GTPγS binding in membranes expressing the same number of histamine H1 receptor binding sites decreased as  
10 levels of Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor cDNA were increased (Figure 12A). Similar results were obtained following co-transfection of Leu<sup>151</sup>Asp α<sub>1b</sub>-adrenoceptor with the histamine H1 receptor-G<sub>11</sub>α in EF88 cells. Histamine stimulation of intracellular [Ca<sup>2+</sup>] was reduced markedly  
15 (Figure 12B).

Co-expression of two distinct GPCRs must result in the presence of the respective homo-dimers as well as providing the potential for hetero-dimer formation. The inventor wished to ensure that the reconstitution of Ca<sup>2+</sup> signalling observed upon co-expression of Leu<sup>133</sup>Asp  
20 histamine H1 receptor-G<sub>11</sub>α with α<sub>1b</sub>-adrenoceptor-Gly<sup>208</sup>Ala G<sub>11</sub>α did not reflect that only α<sub>1b</sub>-adrenoceptor and histamine H1 receptor homo-dimers were present and that the α<sub>1b</sub>-adrenoceptor-Gly<sup>208</sup>Ala G<sub>11</sub>α homo-dimers were simply  
25 able to contact and activate G<sub>11</sub>α linked to Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α homo-dimers. To enhance the

levels of appropriately membrane targetted G protein he generated a construct in which  $G_{11}\alpha$  was linked to the C-terminus of a c-myc-tagged form of the N-terminal and first transmembrane region of the  $\alpha_{1b}$ -adrenoceptor (c-myc-Nt-TM1 $\alpha_{1b}$ - $G_{11}\alpha$ ). When this was transfected into HEK293 cells, immunoblots of membrane fractions clearly demonstrated its expression as a doublet of 53 and 47kDa whether detection was via anti-c-myc (Figure 13A) or anti-G protein antisera (data not shown). Based on immunodetection by the anti-c-myc antibody levels of c-myc-Nt-TM1 $\alpha_{1b}$ - $G_{11}\alpha$  were significantly greater than of the c-myc- $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion protein (Figure 13A). [<sup>35</sup>S]GTP $\gamma$ S binding assays, at the end of which the c-myc-Nt-TM1 $\alpha_{1b}$ - $G_{11}\alpha$  construct was immunoprecipitated with anti-c-myc antibodies, confirmed this construct did not bind [<sup>35</sup>S]GTP $\gamma$ S in response to phenylephrine (Figure 13B). Parallel experiments showed that the anti-c-myc antibodies did capture phenylephrine stimulated binding of [<sup>35</sup>S]GTP $\gamma$ S to the full length c-myc-tagged  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion protein (Figure 13B). However, co-expression of c-myc-Nt-TM1 $\alpha_{1b}$ - $G_{11}\alpha$  with the isolated  $\alpha_{1b}$ -adrenoceptor equally did not result in significant stimulation of [<sup>35</sup>S]GTP $\gamma$ S binding in anti-c-myc immunoprecipitates (Figure 13B) and this was also true when c-myc-Nt-TM1 $\alpha_{1b}$ - $G_{11}\alpha$  was co-expressed with the  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>Ala $G_{11}\alpha$  fusion protein (Figure 13B). Thus, simply increasing the concentration of membrane-associated G protein did not allow  $\alpha_{1b}$ -adrenoceptor or  $\alpha_{1b}$ -adrenoceptor-fusion protein homo-dimers to activate this G protein. This argues strongly that the data from the co-expression of the pairs of inactive histamine H1

receptor and  $\alpha_{1b}$ -adrenoceptor receptor G protein fusions must results from trans-activation within the heterodimer.

5

Example of a Fluorometric Imaging Plate Reader (FLIPR) Assay for the Measurement of Intracellular Calcium Concentration

10 Target Receptor (experimental) and pCMV (negative control) stably transfected cells from respective clonal lines are seeded into poly-D-lysine pretreated 96-well plates (Becton-Dickinson, #356640) at  $5.5 \times 10^4$  cells/well with complete culture medium (DMEM with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate) for assay the next day.

15 To prepare Fluo4-AM (Molecular Probe, #F14202) incubation buffer stock, 1 mg Fluo4-AM is dissolved in 467  $\mu$ l DMSO and 467  $\mu$ l Pluoronic acid (Molecular Probe, #P3000) to give a 1 mM stock solution that can be stored at  $-20^\circ\text{C}$

20 for a month. Fluo4-AM is a fluorescent calcium indicator dye.

Candidate compounds are prepared in wash buffer (1X HBSS/2.5 mM Probenicid/20 mM HEPES at pH 7.4).

25

At the time of assay, culture medium is removed from the wells and the cells are loaded with 100  $\mu$ l of 4  $\mu$ M Fluo4-AM/2.5 mM Probenicid (Sigma, #P8761)/20 mM HEPES/complete medium at pH 7.4. Incubation at  $37^\circ\text{C}/5\% \text{CO}_2$  is allowed to

30 proceed for 60 min.

After the 1 hr incubation, the Fluo4-AM incubation buffer is removed and the cells are washed 2X with 100  $\mu$ l wash buffer. In each well is left 100  $\mu$ l wash buffer. The

plate is returned to the incubator at 37°C/5% CO<sub>2</sub> for 60 min.

5 FLIPR (Fluorometric Imaging Plate Reader; Molecular Device) is programmed to add 50 µl candidate compound on the 30<sup>th</sup> second and to record transient changes in intracellular calcium concentration ([Ca<sup>2+</sup>]) evoked by the candidate compound for another 150 seconds. Total fluorescence change counts are used to determine agonist activity using the FLIPR software. The instrument software normalizes the fluorescent reading to give equivalent initial readings at zero.

15 In some embodiments, the cells comprising Target Receptor further comprise promiscuous G alpha 15/16 or the chimeric Gq/Gi alpha unit.

20 Although the foregoing provides a FLIPR assay for agonist activity using stably transfected cells, a person of ordinary skill in the art would readily be able to modify the assay in order to characterize antagonist activity. Said person of ordinary skill in the art would also readily appreciate that, alternatively, transiently transfected cells could be used.

25

#### Example of a Melanophore assay to detect ligand binding

30 Melanophores are skin cells found in lower vertebrates. They contain pigmented organelles termed melanosomes. Melanophores are able to redistribute these melanosomes along a microtubule network upon G-protein coupled receptor (GPCR) activation. The result of this pigment

movement is an apparent lightening or darkening of the cells. In melanophores, the decreased levels of intracellular cAMP that result from activation of a Gi-coupled receptor cause melanosomes to migrate to the center of the cell, resulting in a dramatic lightening in color. If cAMP levels are then raised, following activation of a Gs-coupled receptor, the melanosomes are re-dispersed and the cells appear dark again. The increased levels of diacylglycerol that result from activation of Gq-coupled receptors can also induce this re-dispersion. In addition, the technology is also suited to the study of certain receptor tyrosine kinases. The response of the melanophores takes place within minutes of receptor activation and results in a simple, robust color change. The response can be easily detected using a conventional absorbance microplate reader or a modest video imaging system. Unlike other skin cells, the melanophores derive from the neural crest and appear to express a full complement of signaling proteins. In particular, the cells express an extremely wide range of G-proteins and so are able to functionally express almost all GPCRs.

Melanophores can be utilized to identify compounds, including natural ligands, against GPCRs. This method can be conducted by introducing test cells of a pigment cell line capable of dispersing or aggregating their pigment in response to a specific stimulus and expressing an exogenous clone coding for the GPCR. A stimulant, e.g., melatonin, sets an initial state of pigment disposition wherein the pigment is aggregated within the test cells if activation of the GPCR induces pigment dispersion. However, stimulating the cell with a

stimulant to set an initial state of pigment disposition wherein the pigment is dispersed if activation of the GPCR induces pigment aggregation. The test cells are then contacted with chemical compounds, and it is  
5 determined whether the pigment disposition in the cells changed from the initial state of pigment disposition. Dispersion of pigments cells due to the candidate compound, including but not limited to a ligand, coupling to the GPCR will appear dark on a petri dish, while  
10 aggregation of pigments cells will appear light.

Materials and methods will be followed according to the disclosure of U.S. Patent Number 5,462,856 and U.S. Patent Number 6,051,386. These patent disclosures are  
15 hereby incorporated by reference in their entirety.

The cells are plated in 96-well plates (one receptor per plate). 48 hours post-transfection, half of the cells on each plate are treated with 10nM melatonin. Melatonin  
20 activates an endogenous Gi-coupled receptor in the melanophores and causes them to aggregate their pigment. The remaining half of the cells are transferred to serum-free medium 0.7X L-15 (Gibco). After one hour, the cells in serum-free media remain in a pigment-dispersed state  
25 while the melatonin-treated cells are in a pigment-aggregated state. At this point, the cells are treated with a dose response of the selected test compound. If the plated GPCRs bound to the selected test compound, the melanophores would be expected to undergo a color change  
30 in response to the compound. If the receptor were either a Gs or Gq coupled receptor, then the melatonin-aggregated melanophores would undergo pigment dispersion. In contrast, if the receptor was a Gi-coupled receptor,

then the pigment-dispersed cells would be expected to undergo a dose-dependent pigment aggregation.

### Discussion

5 By employing fusion proteins between both the  $\alpha_{1b}$ -  
adrenoceptor and the histamine H1 receptor with the G  
protein  $G_{11\alpha}$  the present inventors now show that these  
GPCRs dimerize and that this is not compromised by  
addition of the G protein to the C-terminal tail of the  
10 GPCR. Equally, by employing trFRET to detect GPCR  
dimers/oligomers in intact cells they were able to  
demonstrate the presence of these complexes at the cell  
surface. This also was not compromised by the addition  
of the G protein sequence to the GPCRs. Furthermore, by  
15 introducing mutations that prevent agonist activation of  
the G protein into either the GPCR or the G protein the  
inventors produced pairs of non-functional fusion  
proteins that were able to restore agonist-mediated  
function when co-expressed. Functional reconstitution  
20 was monitored in two ways. Firstly, agonists were able  
to produce elevation of intracellular  $[Ca^{2+}]$  in EF88 cells  
only following co-expression of two mutants that were  
each non-functional in isolation. EF88 cells lack  
expression of phospholipase C-coupled G proteins and thus  
25 it is necessary to introduce both a suitable GPCR and G  
protein into these cells to generate a  $Ca^{2+}$  signal. This  
assay had the obvious benefit that  $Ca^{2+}$  imaging allowed  
the inventors to monitor functional dimerization in  
single cells. One of the earliest steps that can be  
30 measured in the signal transduction cascade is agonist-  
induced guanine nucleotide exchange on the G protein.  
This can be monitored conveniently by the binding of  
 $[^{35}S]GTP\gamma S$ . In all the  $[^{35}S]GTP\gamma S$  binding assays the

inventors initially measured the level of expression of each of the GPCR G protein fusions by using saturation [<sup>3</sup>H]antagonist binding studies. This allowed them to add membrane amounts containing defined quantities of the constructs to the assays. The inventors have previously demonstrated that there is a linear increase in agonist-stimulated [<sup>35</sup>S]GTPγS binding with addition of increasing amounts of a GPCR- G<sub>11</sub>α fusion protein (Stevens et al., 2001). When co-expressing the histamine H1 receptor-Gly<sup>208</sup>Ala G<sub>11</sub>α and Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α fusion proteins, it required the presence of twice the number of [<sup>3</sup>H]antagonist binding sites to generate approximately the same amount of agonist-stimulated [<sup>35</sup>S]GTPγS binding as when only the wild type histamine H1 receptor-G<sub>11</sub>α fusion protein was expressed. This provides good evidence that the functional element is a dimer or a higher order oligomer. If the functional histamine H1 receptor is a dimer, then stochastically, when co-expressing the two non-functional mutant fusions, half of the dimers produced should be non-functional because they will be homodimers of either histamine H1 receptor-Gly<sup>208</sup>Ala G<sub>11</sub>α or Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α. Only 50% of the dimers would be expected to be functional heterodimers containing one copy of histamine H1 receptor-Gly<sup>208</sup>Ala G<sub>11</sub>α and one of Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub>α (Figure 10). These studies also support the idea that, as for the class C GPCRs, aminergic class A GPCRs function via a trans-activation mechanism. The copy of the G protein in the dimer that can be activated is linked to the non-functional form of the GPCR whereas the functional form of the GPCR is associated with non-functional G protein.

In order to further support this mechanism, the inventor took advantage of the known capacity of structural related GPCRs to form hetero-dimers. Initial studies demonstrated that when co-expressed the histamine H1 receptor and the  $\alpha_{1b}$ -adrenoceptor could be co-immunoprecipitated. Furthermore, co-expression in EF88 cells of Leu<sup>133</sup>Asp histamine H1 receptor-G<sub>11</sub> $\alpha$  and  $\alpha_{1b}$ -adrenoceptor-Gly<sup>208</sup>AlaG<sub>11</sub> $\alpha$  resulted in phenylephrine but not histamine-mediated elevation of [Ca<sup>2+</sup>]<sub>i</sub>. This can only occur if the  $\alpha_{1b}$ -adrenoceptor activates the G protein physically linked to the inactive histamine H1 receptor (Figure 2). When the experiment was reversed such that the inactive  $\alpha_{1b}$ -adrenoceptor was linked to the wild type G protein and the wild type histamine H1 receptor linked to the mutant G protein now histamine was functional but phenylephrine was not. The inventor extended this idea by examining the effectiveness of histamine to stimulate binding of [<sup>35</sup>S]GTP $\gamma$ S when the histamine H1 receptor fusion protein was co-expressed with increasing amounts of the isolated but inactive Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor. The effect of histamine was reduced. Such information is consistent with the concept than increasing levels of a histamine H1 receptor-G<sub>11</sub> $\alpha$ -Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor hetero-dimer reduces amounts of the histamine H1 receptor-G<sub>11</sub> $\alpha$  homo-dimer and that histamine binding to the hetero-dimer is unable to activate the G protein that is physically associated with the histamine H1 receptor. In this situation phenylephrine was inactive as Leu<sup>151</sup>Asp  $\alpha_{1b}$ -adrenoceptor is unable to stimulate any G protein. A number of reports have indicated that GPCR-G protein fusions can interact with and activate endogenously expressed G proteins as well as the G protein element of

the fusion (Burt et al., 1998, J. Biol. Chem 273, 10367-10375; Molinari et al., 2003 J. Biol. Chem 278, 15778-15788). However, in these studies the GPCR-G protein fusions have been expressed at very high levels that are within the range in which non-specific 'bystander' (Mercier et al., 2002 J. Biol. Chem 277, 44925-44931) effects have been reported, due to physical proximity in the membrane. Use of EF88 cells eliminated the possibility of interaction with endogenous G proteins as they do not express  $G_q\alpha$  or  $G_{11}\alpha$  and thus effects have to reflect activation of the fused G proteins. Moreover, following introduction of the Gly<sup>208</sup>Ala mutation into the G protein element of the fusions agonist stimulation of [<sup>35</sup>S]GTPγS binding in membranes of transfected HEK293 cells was virtually abolished. This indicates that at the level of expression achieved, there was virtually no activation of endogenous  $G_q\alpha$  or  $G_{11}\alpha$  in HEK293 cells even though both are expressed. In the hetero-dimerisation experiments in HEK293 cells excess G protein is introduced in a 1:1 molar ratio with the second GPCR due to the 1:1 stoichiometry of GPCR and G protein defined by the fusion. To assess if the results could be ascribed simply to the presence of the extra G protein the inventor provided extra G protein via an alternate strategy. To do so he generated a form of  $G_{11}\alpha$  linked to the N-terminal and first transmembrane region of the  $\alpha_{1b}$ -adrenoceptor. Equivalent constructs for other G proteins have been employed previously (Lee et al., 1999 Biochemistry 38, 13801-13809, Guzzi et al., 2001 Biochem J. 355, 323-331, Molinari et al., 2003 J. Biol. Chem 278, 15778-15788) and it has been suggested that the link to a transmembrane  $\alpha$  helix provides the G protein in a

particularly effective orientation for activation (Molinari et al., 2003 as above). Although this construct could be expressed to markedly higher levels than the  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusions, the G protein was not activated by phenylephrine, whether expressed alone or in combination with either the isolated  $\alpha_{1b}$ -adrenoceptor or an  $\alpha_{1b}$ -adrenoceptor- $G_{11}\alpha$  fusion. These studies confirmed that the reconstitution of signal with co-expression of non-functional pairs of GPCR-G protein fusions must reflect an internal transactivation within the reconstituted dimer.

Table 1

gastrointestinal tract smooth muscle	motility of stomach and intestines
gastrointestinal tract ganglionic nerve fibers	motility of stomach and intestines
urinary tract smooth muscle	ureter function and urinary bladder function
salivary gland	salivary secretion
alpha cells of the pancreas	secretion of glucagons
beta cells of the pancreas	secretion of insulin
uterine smooth muscle	uterine contraction
heart muscle	contractility of heart muscle
vascular smooth muscle	contractility of smooth muscle
adipocytes	lipolysis
platelets	platelet aggregation in response to blood vessel injury
skeletal neuromuscular junction	skeletal muscle contractility
bronchial smooth muscle	respiration
nasal mucosal blood vessels	mucosa volume
trigone muscle of bladder and urethra	urinary outflow
chondrocytes	cartilage formation
ciliary body of the eye	aqueous humor production
thyroid	thyroid hormone secretion
mast cells	immediate hypersensitivity reactions
basophils	immediate hypersensitivity reactions
osteoblasts	bone remodeling
osteoclasts	bone remodeling
brain capillary endothelial cells	permeability of blood-brain barrier
T cells	immune response
B cells	immune response
kidney proximal tubular epithelial cells	organic acids exchange
neutrophils	immune response
eosinophils	immune response
monocytes	immune response
kidney late distal tubule	organic bases exchange
collecting duct principal cells	organic bases exchange
kidney granular juxtaglomerular cells	secretion of rennin
peripheral postganglionic adrenergic neurons	sympathetic function

hepatocytes	synthesis of cholesterol and lipoprotein
gastrointestinal parietal cells	secretion of stomach acid
gastrointestinal superficial epithelial cells	secretion of cytoprotective factors, mucus and bicarbonate
epidermal cells	skin maintenance
bone marrow stem cells	erythropoiesis production
angle structures of the eye	aqueous humor outflow
uveoscleral structures of eye	aqueous humor outflow
suprachiasmatic nucleus	circadian rhythm
baroreceptors	blood pressure
basal ganglia	movement control
periaqueductal grey and dorsal horn of spinal cord	nociception
area postrema	vomiting
thalamus	sensorimotor processing and arousal
sensorimotor cerebral cortex	sensorimotor processing
spinal cord motor neurons	motor function control
dorsal root ganglion neurons	sensory information transmission
oligodendrocytes	neuron myelin sheath production
nucleus basalis	cognition and memory
nucleus accumbens	addictive cravings
lateral reticular formation of medulla	vomiting
hypothalamic neurons containing growth hormone releasing factor (GHRH)	secretion of GHRH
hypothalamic neurons containing somatostatin	secretion of somatostatin
hypothalamic neurons containing thyrotropin-releasing hormone (TRH)	secretion of TRH
hypothalamic neurons containing gonadotropin releasing hormone (GnRH)	secretion of GnRH
hypothalamic neurons containing corticotropin releasing factor (CRF)	secretion of CRF
anterior pituitary somatotropes	secretion of growth hormone
anterior pituitary lactotropes	secretion of prolactin
anterior pituitary gonadotropes	secretion of luteinizing hormone
anterior pituitary gonadotropes	secretion of follicle stimulating hormone
anterior pituitary corticotropes	secretion of adrenocorticotrophic hormone
leydig cells of the testes	secretion of testosterone
sertoli cells of the testes	spermatogenesis

granulosa cells of the ovary	synthesis of estrogen
theca cells of the ovary	synthesis of estrogen
synovium	joint function
amygdala	modulation of emotion
pineal gland	regulation of circadian rhythm
nucleus of the solitary tract	cardiovascular regulation
caudal ventrolateral medulla	cardiovascular regulation
rostral ventrolateral medulla	vasopressor activity
parabrachial nucleus	taste aversion response and nociceptive response
entorhinal cortex	cognition
piriform cortex	cognition
temporal cortex	memory acquisition
frontal cortex	regulation of emotional response and memory acquisition
parietal cortex	visual acuity, touch perception, and voluntary movement
occipital cortex	visual acuity
hippocampus	learning and memory
dentate gyrus	learning and memory
midbrain reticular formation	arousal
supraoptic nucleus of the hypothalamus	reproductive functions
magnocellular of the hypothalamus	modulation of stress, blood pressure and lactation
parvocellular neurons of the hypothalamus	metabolism
arcuate nucleus of the hypothalamus	release of pituitary hormones
trigeminal area	cerebral vessel dilation and blood pressure
cerebral blood vessels	cerebral vessel dilation
brain stem	breathing, heart rate, startle responses, sweating, blood pressure, digestion and body temperature
ventral lamina terminalis	blood pressure
vagus nerve	blood pressure and heart rate
nucleus of the solitary tract	blood pressure
adrenal medulla	catecholamine response to stress
adrenal cortex	stress-induced corticosterone release
locus coeruleus	arousal and response to stress
substantia nigra	control of body movement
ventral tegmental area	control of body movement
olfactory bulb	odor perception
median eminence of hypothalamus	pituitary function

raphe nuclei	sleep and arousal
habenula	sexual activity
cerebellum	control of body movement
posterior hypothalamus	intestinal motility and blood pressure
dorsal medulla	blood pressure
lateral hypothalamus	food intake and stomach acid secretion
rostral hypothalamus	heart rate
pontine-medullary reticular formation	respiration and heart rate
medulla	respiration and heart rate
mesencephalon	heart rate
ventral hypothalamus	response to stress
paraventricular nucleus of hypothalamus	response to stress
preoptic area of hypothalamus	sexual activity
mammillary region	food intake
perifornical area of hypothalamus	food intake
ventromedial hypothalamus	food intake
pons	reticular formation
septum	emotional control
pedunculopontine tegmental nucleus	arousal
astrocytes	neuronal metabolism
microglia	response to neuronal injury
choroid plexus	production of cerebrospinal fluid
Schwann cells	myelination of peripheral nerves
endoneurium	production of connective tissue nerve sheath
lateral spinothalamic pathway	response to pain and temperature stimuli
ventral spinothalamic pathway	touch sensation
dorsal column-medial lemniscal pathway	touch sensation
free nerve endings	response to pain and temperature
hair follicle endings	touch sensation
Krause's end-bulb	temperature sensation
Meissner's corpuscles	touch-pressure sensation
Merkel's disk	touch-pressure sensation
Pacinian corpuscle	touch-pressure sensation
Ruffini's corpuscle	temperature sensation
retina	visual acuity
parathyroid gland	calcium balance
placenta	placental activity
skeletal muscle fibers	muscle contraction

copora cavernosum	genital vasodilation
corticospinal tract	movement control
motor cerebral cortex	movement control
postganglionic neurons	control of blood pressure and adrenal activity
intramural ganglion	distal colon peristalsis
hypogastric plexus	control of urethral and anal sphincters
pelvic plexus	genital vasodilatation and penile erection
vesical plexus	urinary bladder control
celiac plexus	intestinal peristolisis.

References

1. Bouvier, M. (2001) *Nat. Rev. Neurosci.* 2, 274-286.
- 5 2. Carrillo J.J., Stevens P.A. and Milligan G. (2002)  
*J. Pharmacol. Exp. Ther.* 302, 1080-1088.
3. Devi, L.A. (2001) *Trends Pharmacol. Sci.* 22, 532-  
537.
- 10 4. Duthey B., Caudron S., Perroy J., Bettler B., Fagni  
L., Pin J.P., Prezeau L. (2002) *J Biol Chem.* 277, 3236-  
3241.
- 15 5. George S.R., O'Dowd B.F., Lee S.P., (2002) *Nat Rev*  
*Drug Discov.* 1, 808-820.
6. Gohla A., Offermanns S., Wilkie T.M. and Schultz G.  
(1999) *J. Biol. Chem.* 274, 17901-17907.
- 20 7. Greasley P.J., Fanelli F., Scheer A., Abuin L.,  
Nenniger-Tosato M., DeBenedetti P.G., Cotecchia S. (2001)
8. Lee DK, et al., Orphan-G-protein coupled receptors  
25 in *CND*, *Curr Opin, Pharmacol.* (2001) 1, 31-39.
9. Lee C., Ji I., Ryu K., Song Y., Conn P.M., Ji TH.  
(2002) *J Biol Chem* 277, 15795-15800.
- 30 10. Liu S., Carrillo J.J., Padiani J. and Milligan G.  
(2002) *J. Biol. Chem.* 277, 25707-25714.

11. Mao J., Yuan H., Xie W., Simon M.I. and Wu D. (1998) *J. Biol. Chem.* 273, 27118-27123.
12. McVey M., Ramsay D., Kellett E., Rees S., Wilson S., Pope A.J. and Milligan G. (2001) *J. Biol. Chem.* 276, 14092-14099.  
5
13. Milligan G. (2000) *Trends Pharmacol. Sci.* 21: 24-28.
14. Milligan G (2001) *J. Cell Sci.* 114, 1265-1271.  
10
15. Milligan G. (2002) *Methods Enzymol.* 343: 260-273.
16. Mitchell F.M., Buckley N.J. and Milligan G. (1993) *Biochem. J.* 293, 495-499.  
15
17. Mitchell, F.M., Mullaney, I., Godfrey, P.P., Arkinstall, S.J., Wakelam, M.J.O. and Milligan, G. (1991) *FEBS Lett.* 287, 171-174.
- 20 18. Offermanns S., Zhao L.P., Gohla A., Sarosi I., Simon M.I. and Wilkie T.M. (1998) *EMBO J.* 17, 4304-4312.
- 25 19. Salim K., Fenton T., Bacha J., Urien-Rodriguez H., Bonnert T., Skynner H.A., Watts E., Kerby J., Heald, A., Beer M., McAllister G. and Guest P.C. (2002) *J Biol Chem.* 277, 15482-15485.
- 30 20. Stevens P.A., Padiani J., Carrillo J.J. and Milligan G. (2001) *J. Biol. Chem.* 276, 35883-35890.
21. Yu R. and Hinkle P.M. (1999) *J. Biol. Chem.* 274, 15745-15750.

## Claims

1. A biological reagent comprising a complex having
  - 5 (a) a first GPCR associated with a first G-protein wherein the first GPCR is non-functional with respect to the associated first G-protein;
  - (b) a second GPCR associated with a second G-protein  
10 wherein the second G-protein is non-functional.
2. A biological reagent according to claim 1 wherein the complex is present in a cell membrane.
- 15 3. A biological reagent according to claim 1 or claim 2 wherein the first GPCR and first G-protein are associated as a fusion protein, and wherein the second GPCR and second G-protein are associated as a fusion protein.
- 20 4. A biological reagent according to any one of the preceding claims wherein the first GPCR has a modified amino acid sequence compared to the native GPCR sequence so as to render it non-functional with respect to the first G-protein.  
25
5. A biological reagent according to claim 4 wherein the amino acid sequence of the first GPCR is modified within the 2<sup>nd</sup> intracellular loop.
- 30 6. A biological reagent according to claim 4 or claim 5 wherein the amino acid sequence of the first GPCR is modified by amino acid residue substitution.

7. A biological reagent according to claim 6 wherein the amino acid sequence of the first GPCR is modified by a substitution of a hydrophobic amino acid residue to an acidic amino acid residue.

5

8. A biological reagent according to any one of claims 4 to 7 wherein the first GPCR has a 2<sup>nd</sup> intracellular loop amino acid sequence selected from the group shown in Fig 3 and one or more of the highlighted amino acid residues are modified.

10

9. A biological reagent according to any one of the preceding claims wherein the second G-protein has a modified amino acid sequence compared to the native G-protein so as to render it non-functional.

15

10. A biological reagent according to claim 9 wherein the second G-protein is modified as compared to the native amino acid sequence by at least one amino acid residue substitution.

20

11. A biological reagent according to claim 10 wherein the amino acid residue substituted is glycine.

25

12. A biological reagent according to any one of the previous claims wherein the first and second GPCRs are class A GPCRs.

30

13. A biological reagent according to claim 12 wherein the class A GPCRs are selected from the group provided in Fig. 3.

14. A biological reagent according to any one of the preceding claims wherein the first GPCR is different to the second GPCR.

5 15. A fusion protein comprising a GPCR and a G-protein, wherein the GPCR maintains the ability to bind ligand but is modified with respect to the wild-type GPCR such that it is incapable of stimulating said G-protein following ligand binding.

10

16. A fusion protein according to claim 15 wherein the amino acid sequence of the GPCR is modified within the 2<sup>nd</sup> intracellular loop.

15 17. A fusion protein according to claim 15 or claim 16 wherein the amino acid sequence of the GPCR is modified by amino acid residue substitution.

20 18. A fusion protein according to claim 17 wherein the amino acid sequence of the GPCR is modified by a substitution of a hydrophobic amino acid residue to an acidic amino acid residue.

25 19. A fusion protein according to any one of claims 15 to 18 wherein the GPCR has a 2<sup>nd</sup> intracellular loop amino acid sequence selected from the group shown in Fig 3 and one or more of the highlighted amino acid residues are modified.

30 20. A fusion protein comprising a GPCR and a G-protein, wherein the G-protein is modified with respect to its wild type such that it is non-functional.

21. A fusion protein according to claim 20 wherein the G-protein has a modified amino acid sequence compared to the wild type G-protein so as to render it non-functional.

5

22. A fusion protein according to claim 21 wherein the G-protein is modified as compared to the wild type amino acid sequence by at least one amino acid residue substitution.

10

23. A fusion protein according to claim 22 wherein the amino acid residue substituted is glycine.

15

24. An isolated nucleic acid sequence encoding a fusion protein according to any one of claims 15 to 23.

25. An expression vector comprising a nucleic acid sequence according to claim 24.

20

26. A host cell comprising a nucleic acid sequence according to claim 24 or an expression vector according to claim 25.

25

27. A method of producing a biological reagent according to any one of claims 1 to 14 comprising the step of

(a) expressing a first nucleic acid construct in a cell, said nucleic acid construct encoding a first GPCR/G-protein fusion protein wherein the GPCR is mutated as compared to the wild-type GPCR thereby rendering it non-functional with respect to its G-protein;

30

(b) expressing a second nucleic acid construct in said cell, said second nucleic acid construct encoding a second GPCR/G-protein fusion protein wherein the G-

protein is mutated as compared to the wild-type G-protein thereby rendering it non-functional;

(c) allowing said first and second fusion proteins to assemble into a complex in the cell membrane.

5

28. A method of producing a biological reagent according to any one of claims 1 to 14, said method comprising the steps of

10 (a) producing a first nucleic acid construct encoding a fusion protein of a first GPCR and a first G-protein wherein the first GPCR is mutated as compared to the wild-type such that it is non-functional with respect to the fused G-protein;

15 (b) producing a second nucleic acid construct encoding a fusion protein of a second GPCR and a second G-protein wherein the second G-protein is mutated as compared to the wild-type rendering it non-functional;

20 (c) co-expressing the first and second nucleic acid constructs in a cell so as to produce a complex comprising said first and second GPCRs.

29. A method according to claim 27 or claim 28 further comprising the step

25 (d) isolating a part of the cell membrane comprising the complex.

30 30. A method according to any one of claims 27 to 29 wherein the first GPCR is mutated as compared to its wild-type GPCR by substitution of at least one amino acid residue.

31. A method according to claim 30 wherein the at least one amino acid is present in the 2<sup>nd</sup> intracellular loop of the GPCR.

5 32. A method according to claim 31 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

10 33. A method according to claim 31 or claim 32 wherein the 2<sup>nd</sup> intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

15 34. A method according to any one of claims 27 to 33 wherein the second G-protein is mutated as compared to the wild-type G-protein by substitution of at least one amino acid residue.

20 35. A method according to claim 34 wherein the amino acid residue substituted is glycine.

36. A method according to any one of claims 27 to 35 wherein the first and second GPCRs are class A GPCRs.

25

37. A method according to claim 36 wherein the class A GPCRs are selected from the group provided in Fig. 3.

30 38. A method according to any one of claims 27 to 37 wherein the first GPCR is different to the second GPCR.

39. A method of determining a first and second GPCR having affinity for each other such that they form a GPCR oligomer, said method comprising the steps of

(a) producing a first nucleic acid construct  
5 encoding a first GPCR and its associated G-protein as a fusion protein wherein the GPCR is mutated as compared to its native GPCR so that it is non-functional with respect to its associated G-protein;

(b) producing a second nucleic acid construct  
10 encoding a second GPCR and its associated G-protein as a fusion protein wherein the G-protein is mutated as compared to its native G-protein so that it is non-functional;

(c) co-expressing said first and second nucleic acid  
15 constructs in a cell; and

(d) determining the presence of a complex comprising said first and second GPCRs.

40. A method according to claim 39 wherein the presence  
20 of a complex is determined by contacting the cell with a ligand for said second GPCR and determining whether said first G-protein is activated.

41. A method according to claim 39 or claims 40 wherein  
25 the first GPCR is mutated as compared to its native GPCR by substitution of at least one amino acid residue.

42. A method according to claim 41 wherein the at least  
30 one amino acid is present in the 2<sup>nd</sup> intracellular loop of the GPCR.

43. A method according to claim 42 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

5 44. A method according to claim 42 or claim 43 wherein the 2<sup>nd</sup> intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

10

45. A method according to any one of claims 39 to 44 wherein the second G-protein is mutated as compared to the native G-protein by substitution of at least one amino acid residue.

15

46. A method according to claim 45 wherein the amino acid residue substituted is glycine.

20

47. A method according to any one of claims 39 to 46 wherein the first and second GPCRs are class A GPCRs.

48. A method according to claim 47 wherein the class A GPCRs are selected from the group provided in Fig. 3.

25

49. A method according to any one of claims 39 to 48 wherein said first and second GPCRs are different.

30

50. A method according to any one of claims 39 to 49 wherein the wild-type first and second GPCRs are endogenously co-expressed by at least one cell type.

51. A method for determining the presence of a new or altered ligand binding site resulting from GPCR oligomerisation, said method comprising the steps of

5 a) contacting a compound with a first cell expressing a GPCR oligomer having (i) a first GPCR associated with a G-protein wherein the first GPCR is modified such that it is non-functional with respect to said G protein; and (ii) a second GPCR associated with a G-protein wherein the G-protein is modified so that it is  
10 non-functional;

b) contacting said compound with a second cell expressing an unmodified first GPCR and/or contacting said compound with a second cell expressing an unmodified second GPCR; and

15 c) comparing the effect of the compound on the first cell and the second cell to determine the presence of a new or modified ligand binding site created by the GPCR oligomer.

20 52. A method for determining a change in GPCR function as a result of forming a GPCR oligomer, said method comprising

25 a) contacting a compound with a first cell expressing a GPCR oligomer having (i) a first GPCR associated with a G-protein wherein the first GPCR is modified such that it is non-functional with respect to said G protein; and (ii) a second GPCR associated with a G-protein wherein the G-protein is modified so that it is non-functional;

30 b) contacting said compound with a second cell expressing an unmodified first GPCR and/or a second cell expressing an unmodified second GPCR; and

(c) comparing the function of said GPCR oligomer with that of said unmodified first GPCR and/or with that of said second GPCR to determine a change in receptor function resulting from oligomerisation.

5

53. A method according to claim 52 wherein the change in receptor function is a change in compound potency.

54. A method according to claim 52 wherein the change in receptor function is a change in cellular signalling pathway resulting from receptor activation by said compound.

10

55. A method according to any one of claims 51 to 54 wherein the first GPCR is mutated as compared to its native GPCR by substitution of at least one amino acid residue.

15

56. A method according to claim 55 wherein the at least one amino acid is present in the 2<sup>nd</sup> intracellular loop of the GPCR.

20

57. A method according to claim 55 or claim 56 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

25

58. A method according to claim 56 or claim 57 wherein the 2<sup>nd</sup> intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

30

59. A method according to any one of claims 51 to 58 wherein the second G-protein is mutated as compared to the native G-protein by substitution of at least one amino acid residue.

5

60. A method according to claim 59 wherein the amino acid residue substituted is glycine.

10

61. A method according to any one of claims 51 to 60 wherein the first and second GPCRs are class A GPCRs.

62. A method according to claim 61 wherein the class A GPCRs are selected from the group provided in Fig. 3.

15

63. A method according to any one of claims 51 to 62 wherein said first and second GPCRs are different.

64. A method of determining an effect a compound has on a GPCR oligomer, comprising the steps of:

20

a) contacting said compound with a first cell expressing a GPCR oligomer having (i) a first GPCR associated with a G-protein wherein the first GPCR is modified such that it is non-functional with respect to said G protein; and (ii) a second GPCR associated with a G-protein wherein the G-protein is modified so that it is non-functional;

25

b) detecting the presence of a cellular signal resulting from contact between said compound and said GPCR oligomer; and

30

c) determining an effect said compound has on the GPCR oligomer.

65. A method according to claim 64 wherein the first GPCR is mutated as compared to its wild-type GPCR by substitution of at least one amino acid residue.

5 66. A method according to claim 65 wherein the at least one amino acid is present in the 2nd intracellular loop of the GPCR.

10 67. A method according to claim 66 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

15 68. A method according to claim 65 or claim 66 wherein the 2nd intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

20 69. A method according to any one of claims 64 to 68 wherein the second G-protein is mutated as compared to the wild-type G-protein by substitution of at least one amino acid residue.

25 70. A method according to claim 69 wherein the amino acid residue substituted is glycine.

71. A method according to any one of claims 64 to 70 wherein the first and second GPCRs are class A GPCRs.

30 72. A method according to claim 71 wherein the class A GPCRs are selected from the group provided in Fig. 3.

73. A method according to any one of claims 64 to 72 wherein said first and second GPCRs are different.

74. A method according to any one of claims 64 to 73 further comprising the step of comparing said effect with that resulting from contact between said compound and an unmodified first GPCR and/or with that resulting from contact between said compound and an unmodified second GPCR.

75. A method of identifying a compound capable of interacting with a GPCR oligomer, said method comprising the steps of

- a) providing a cell expressing a biological reagent according to any one of claims 1 to 14;
- b) contacting said biological reagent with said compound; and
- c) determining whether said compound interacts with the GPCR oligomer.

76. A method according to claim 75 wherein interaction between the compound and the GPCR oligomer is determined by identifying the presence of a cellular signal resulting from said interaction.

77. A method according to claim 76 wherein the cellular signal is determined by the presence of  $\text{Ca}^{2+}$ , cAMP, inositol 1,4,5 triphosphate levels, protein kinase C activation, MAP kinase activation.

78. A method according to claim 76 wherein said cellular signal is determined using a reporter assay.

79. A method according to claim 75 or claim 76 wherein said cell is a pigment cell and the cellular signal is determined by a change in the aggregation state of pigment in the cell.

5

80. A method according to claim 79 wherein the pigment cell is a melanocyte.

10

81. A method according to any one of claims 75 to 80 wherein said compound interacts with said GPCR oligomer as an agonist, antagonist or an inverse agonist.

15

82. A method according to any one of claims 75 to 81 wherein the first GPCR is mutated as compared to its wild-type GPCR by substitution of at least one amino acid residue.

20

83. A method according to claim 82 wherein the at least one amino acid is present in the 2nd intracellular loop of the GPCR.

25

84. A method according to claim 83 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

30

85. A method according to claim 82 or claim 83 wherein the 2nd intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

86. A method according to any one of claims 75 to 85 wherein the second G-protein is mutated as compared to

the wild-type G-protein by substitution of at least one amino acid residue.

5 87. A method according to claim 86 wherein the amino acid residue substituted is glycine.

88. A method according to any one of claims 75 to 87 wherein the first and second GPCRs are class A GPCRs.

10 89. A method according to claim 88 wherein the class A GPCRs are selected from the group provided in Fig. 3.

90. A method of identifying a compound having the ability to modulate binding between a GPCR oligomer and its ligand, said method comprising

15 a) providing a cell expressing a GPCR oligomer comprising a (i) a first GPCR associated with a first G-protein wherein the GPCR is non-functional with respect to the G-protein; (ii) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional;

20 b) contacting said cell with a test compound in the presence of said ligand; and

25 c) comparing the ability of said ligand to bind GPCR oligomer with the ability of said ligand to bind the GPCR oligomer under comparable conditions but in the absence of said compound.

30 91. A method according to claim 90 wherein said compound is a protein.

92. A method according to claim 91 wherein the protein is a third GPCR.

93. A method according to claim 92 wherein said first, second and third GPCR are endogenously coexpressed by at least one cell type.

5

94. A method according to any one of claims 90 to 93 wherein said ligand binds to a new or altered ligand binding site determined to be present on the oligomer by a method according to any one of claims 51, and 55 to 74.

10

95. A method according to any one of claims 90 to 94 wherein the first GPCR is mutated as compared to its wild-type GPCR by substitution of at least one amino acid residue.

15

96. A method according to claim 95 wherein the at least one amino acid is present in the 2nd intracellular loop of the GPCR.

20

97. A method according to claim 96 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

25

98. A method according to claim 95 or claim 96 wherein the 2nd intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

30

99. A method according to any one of claims 90 to 98 wherein the second G-protein is mutated as compared to the wild-type G-protein by substitution of at least one amino acid residue.

100. A method according to claim 99 wherein the amino acid residue substituted is glycine.

5 101. A method according to any one of claims 90 to 100 wherein the first and second GPCRs are class A GPCRs.

102. A method according to claim 101 wherein the class A GPCRs are selected from the group provided in Fig. 3.

10

103. A method for evaluating differential G-protein coupling comprising the steps of

15 (a) providing a first cell expressing a GPCR oligomer comprising (i) a first GPCR associated with a first G protein wherein the GPCR is non-functional with respect to the G-protein; (ii) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional;

20 (b) providing a second cell expressing a GPCR oligomer comprising (i) said first GPCR associated with said first G-protein wherein said first GPCR is functional and said G-protein is non-functional; (ii) said second GPCR associated with said second G-protein wherein said second GPCR is non-functional with respect to G-protein;

25 (c) providing a control cell expressing a monomer of said first GPCR associated with said first G-protein wherein both the GPCR and the G-protein are functional;

30 (d) contacting said first, second and control cell with a compound capable of binding to the ligand binding site present on the first and/or the second GPCR;

(e) repeating steps (a) to (d) with a different first and/or second G-protein; and

(f) evaluating differential G-protein coupling.

104. A method according to claim 103 wherein the first  
and second G-protein is selected from Gs, Gi, Gq, G11,  
5 G12, G13, G15, G16, Go or Gz.

105. A method according to claim 103 wherein said first  
and second G-protein is selected from a G-protein that  
modulates an intracellular level selected from Ca<sup>2+</sup>, cAMP,  
10 cGMP, inositol 1, 4, 5 triphosphate, diacylglycerol,  
protein kinase C activity, or MAP kinase activity.

106. A method according to any one of claims 103 to 105  
wherein the first and second GPCR are the same.

15

107. A method according to any one of claims 103 to 106  
wherein the first and second GPCR are different.

108. A method according to claim 103 wherein the wild  
20 type first and second GPCR are endogenously co-expressed  
in at least one cell type.

109. A method according to any one of claims 103 to 108  
wherein the first GPCR is mutated as compared to its  
25 wild-type GPCR by substitution of at least one amino acid  
residue.

110. A method according to claim 109 wherein the at least  
one amino acid is present in the 2nd intracellular loop  
30 of the GPCR.

111. A method according to claim 110 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

5 112. A method according to claim 109 or claim 110 wherein the 2nd intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

10

113. A method according to any one of claims 103 to 112 wherein the second G-protein is mutated as compared to the wild-type G-protein by substitution of at least one amino acid residue.

15

114. A method according to claim 113 wherein the amino acid residue substituted is glycine.

20

115. A method according to any one of claims 103 to 114 wherein the first and second GPCRs are class A GPCRs.

116. A method according to claim 115 wherein the class A GPCRs are selected from the group provided in Fig. 3.

25

117. A method for evaluating differential G-protein coupling for a GPCR comprising the steps of:

30

(a) providing a first cell expressing a GPCR oligomer comprising (i) a first GPCR associated with a first G-protein wherein the GPCR is non-functional with respect to the G-protein; (ii) the second GPCR associated with a second G-protein wherein the second G-protein is non-functional;

(b) providing a second cell expressing the second GPCR associated with the first G-protein wherein both the GPCR and the G-protein are functional;

5 (c) contacting said first and second cells with a compound capable of binding to the ligand binding site present on the second GPCR;

(d) repeating steps (a) to (c) one or more times with a different first G-protein;

10 (e) optionally repeating steps (a) to (d) one or more times with a different first GPCR; and

(f) evaluating differential G-protein coupling by the second GPCR.

118. A method according to claim 117 wherein the first  
15 and second G-protein is selected from Gs, Gi, Gq, G11, G12, G13, G15, G16, Go or Gz.

119. A method according to claim 117 wherein said first  
20 and second G-protein is selected from a G-protein that modulates an intracellular level selected from Ca<sup>2+</sup>, cAMP, cGMP, inositol 1, 4, 5 triphosphate, diacylglycerol, protein kinase C activity, or MAP kinase activity.

120. A method according to any one of claims 117 to 119  
25 wherein the first and second GPCR are different.

121. A method according to claim 120 wherein the wild-type first and second GPCR are endogenously co-expressed  
in at least one cell type.

30

122. A method according to any one of claims 117 to 121 wherein the first GPCR is mutated as compared to its

wild-type GPCR by substitution of at least one amino acid residue.

5 123. A method according to claim 122 wherein the at least one amino acid is present in the 2nd intracellular loop of the GPCR.

10 124. A method according to claim 123 wherein the at least one amino acid is a hydrophobic amino acid residue and is substituted for an acidic amino acid residue.

15 125. A method according to claim 122 or claim 123 wherein the 2nd intracellular loop has a sequence selected from the group shown in Fig. 3 and the at least one amino acid residue is selected from the amino acid residues highlighted.

20 126 A method according to any one of claims 117 to 125 wherein the second G-protein is mutated as compared to the wild-type G-protein by substitution of at least one amino acid residue.

25 127. A method according to claim 126 wherein the amino acid residue substituted is glycine.

128. A method according to any one of claims 117 to 127 wherein the first and second GPCRs are class A GPCRs.

30 129. A method according to claim 128 wherein the class A GPCRs are selected from the group provided in Fig. 3.

130. A method of producing a pharmaceutical composition comprising a compound capable of interacting with a GPCR oligomer, said method comprising the steps of

- 5 a) providing a cell expressing a biological reagent according to any one of claims 1 to 14;
- b) contacting said biological reagent with said compound;
- c) determining whether said compound interacts with the GPCR oligomer; and
- 10 d) mixing said compound with a pharmaceutically acceptable carrier so as to produce a pharmaceutical composition.

131. A method of producing a pharmaceutical composition comprising a compound having the ability to modulate binding between a GPCR oligomer and its ligand, said method comprising

- 15 a) producing a cell expressing a GPCR oligomer comprising a (i) a first GPCR associated with a first G-protein wherein the GPCR is non-functional with respect to the G-protein; (ii) a second GPCR associated with a second G-protein wherein the second G-protein is non-functional;
- 20 b) contacting said cell with a test compound in the presence of said ligand;
- 25 c) comparing the ability of said ligand to bind GPCR oligomer with the ability of said ligand to bind the GPCR oligomer under comparable conditions but in the absence of said compound; and
- 30 d) mixing said compound with a pharmaceutical acceptable carrier so as to produce a pharmaceutical composition.

132. A method of treating a disorder in an individual, comprising administering to said individual an effective amount of the compound identified according to 75 or 90, wherein said disorder is related to a cell type known to endogenously coexpress said first GPCR and said second GPCR.

133. The method of claim 132, wherein said first GPCR and said second GPCR are coexpressed by a cell type included in Table 1.

134. The method of claim 132 or claim 133, wherein said compound is an agonist and said disorder is alleviated by increasing the activity of the oligomer.

135. The method of claim 132 or claim 133, wherein said compound is an antagonist and said disorder is alleviated by decreasing the activity of the oligomer.

136. The method of claim 132 or claim 133, wherein said compound is an inverse agonist and said disorder is alleviated by decreasing the activity of the oligomer.

137. A method of treating a disorder in an individual, comprising administering to said individual an effective amount of the compound identified according to the method of claim 75 or claim 90, wherein said disorder is related to a cell type known to endogenously coexpress said first GPCR and said second GPCR.

138. The method of claim 137, wherein said first GPCR and said second GPCR are coexpressed by a cell type included in Table 1.

139. The method of claim 137 or claim 138, wherein said  
ligand is an agonist, said compound increases the binding  
of said agonist to said oligomer, and said disorder is  
5 alleviated by increasing the activity of the oligomer.

140. The method of claim 137 or claim 138, wherein said  
ligand is an agonist, said compound decreases the binding  
of said agonist to said oligomer, and said disorder is  
10 alleviated by decreasing the activity of the oligomer.

141. The method of claim 137 or claim 138, wherein said  
ligand is an antagonist, said compound increases the  
binding of said antagonist to said oligomer, and said  
15 disorder is alleviated by decreasing the activity of the  
oligomer.

142. The method of claim 137 or claim 138, wherein said  
ligand is an antagonist, said compound decreases the  
20 binding of said antagonist to said oligomer, and said  
disorder is alleviated by increasing the activity of the  
oligomer.

143. The method of claim 137 or claim 138, wherein said  
25 ligand is an inverse agonist, said compound increases the  
binding of said inverse agonist to said oligomer, and  
said disorder is alleviated by decreasing the activity of  
the oligomer.

30 144. The method of claim 137 or claim 138, wherein said  
ligand is an inverse agonist, said compound decreases the  
binding of said inverse agonist to said oligomer, and

said disorder is alleviated by increasing the activity of the oligomer.



2/14




Figure 2

3/14

GPCR	specie	G protein	Aminoacid sequence (2 <sup>nd</sup> intracellular loop)
5HT1A receptor	human	Gi/Go	DRYWAITDPTD
5HT1B receptor	mouse	Gi/Go	DRYWAITDAVE
5HT1D receptor	rabbit	Gi/Go	DRYWAITDALE
5HT2A receptor	rat	Gq/G11	DRYVATQNPIH
5HT2C receptor	rat	Gq/G11	DRYVATRNPIE
5HT4 receptor	mouse	Gs	DRYVATCCQEL
5HT6 receptor	rat	Gs	DRYLLTLLSELR
$\alpha$ 1a adrenergic receptor	bovine	Gq/G11	DRYIGVSYPLR
$\alpha$ 1b adrenergic receptor	hamster	Gq/G11	DRYIGVRYSLQ
$\alpha$ 2b adrenergic receptor	rat	Gi/Go	DRYWAIVSRALE
$\beta$ 1 adrenergic receptor	human	Gs	DRYLATITSEPR
$\beta$ 2 adrenergic receptor	bovine	Gs	DRYLATITSEPK
$\beta$ 3 adrenergic receptor	mouse	Gs	DRYLATITNPLR
A1 adenosine receptor	human	Gi/Go	DRYLRVVKIPLR
A3 adenosine receptor	human	Gi/Go	DRYLRVVKLTVR
M1 receptor	mouse	Gq/G11	DRYFVITREPLS
M2 receptor	human	Gi/Go	DRYFCVTKPLT
M3 receptor	mouse	Gi/Go	DRYFSTITREPLT
Melanocortin2 receptor	human	Gs	DRYITTFHALR
AT1A receptor	human	Gq/G11	DRYLATVHPMK
AT1B receptor	rat	Gq/G11	DRYLATVHPMK
B2 bradikinin receptor	human	Gq/G11	DRYLATVKTMS
CXCR3	mouse	Gi/Go	DRYLSITVHATQ
CXCR4	human	Gi/Go	DRYLATVHATN
D2 receptor	mouse	Gi/Go	DRYTAVAMPML
D3 receptor	rat	Gi/Go	DRYTAVMPEVH
FSHR	bovine	Gs	ERWHTITHAMQ
GRHR	mouse	Gq/G11	DRSLATIQPLA
H1 receptor	mouse	Gq/G11	DRYRSVQQPLR
H2 receptor	human	Gs	DRYCAVMDPLR
LSHR	mouse	Gs	ERWHTITVAVQ
$\delta$ opioid receptor 1	rat	Gi/Go, Gz	DRYIAVCHPEVK
$\kappa$ opioid receptor 1	mouse	Gi/Go	DRYIAVCHPEVK
$\mu$ opioid receptor 1	rat	Gi/Go, Gz	DRYIAVCHPEVK
rhodopsin	bovine	Gt	ERYVVVCKPMS
Oxytocin receptor	rat	Gq/G11	DRCLATCQPLR
P2U purinoceptor 1	rat	Gq/G11	HRCLGVLRPLH
Prostaglandin D2 receptor	mouse	Gs	ECWLSLGHPEF
Prostaglandin E2 recptor(E1)	rat	Gq/G11	ERCVGVITQPLI
Somatostatin receptor 2	human	Gi/Go Gq	DRYLAIVHPEIK
TRH receptor	rat	Gq/G11	ERYIATCHEPIK
Vasopresin 1A receptor		Gq/G11	DRYIAVCHPEIK

Figure 3

# Reconstitution of GTP $\gamma$ S binding by crosstalk between fusion proteins




Figure 4

5/14

Reconstitution of GTP $\gamma$ S binding by  
 crosstalk between H<sub>1</sub>/G $\alpha$ <sub>11</sub> fusion proteins






Figure 5

**Histamine induced increase in  
[Ca<sup>++</sup>] in Gq/G11 minus EF88  
cells transfected with H<sub>1</sub>/Gα<sub>11</sub>**

**B**



**A**




**Figure 6**

Black = wild type fusion  
 Blue = H1-G<sup>208</sup>A-G11α  
 Green = L<sup>133</sup>D H1-G11α  
 Red = combination

7/14

+ H<sub>1</sub> L133D -G<sub>11α</sub> fusion protein + Hamster α<sub>1b</sub>-G<sub>11α</sub> G208A fusion protein




+ Histamine (1 mM) + Phe (10 μM)

Figure 7a

8/14

+ Hamster  $\alpha_{1b}$  L151D-G<sub>11 $\alpha$</sub>  fusion protein + H<sub>1</sub>-G<sub>11 $\alpha$</sub>  G208A fusion protein




+ Phe (10  $\mu$ M)      + Histamine (1 mM)


Figure 7b

9/14

**A**




**B**



**Figure 8**

10/14

**A**



**B**




Figure 9

A + B

BB

AB BA

AA

Non-functional


Functional

Non-functional

Figure 10

12/14

**A**



**B**




Figure 11

13/14





Figure 12

14/14

**A**



**B**




Figure 13

# INTERNATIONAL SEARCH REPORT

/GB2004/002150

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C07K14/705 C07K14/72 G01N33/68 G01N33/566		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, EMBASE		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	-/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input type="checkbox"/> Patent family members are listed in annex.		
° Special categories of cited documents :		
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
*E* earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
*O* document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family	
*P* document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search  <p style="text-align: center;">23 September 2004</p>	Date of mailing of the international search report  <p style="text-align: center;">07/10/2004</p>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  <p style="text-align: center;">Steffen, P</p>	

## INTERNATIONAL SEARCH REPORT

PCT/GB2004/002150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MOLINARI PAOLA ET AL: "Promiscuous coupling at receptor-Galpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another."            THE JOURNAL OF BIOLOGICAL CHEMISTRY. 2 MAY 2003,            vol. 278, no. 18, 2 May 2003 (2003-05-02),            pages 15778-15788, XP002297484            ISSN: 0021-9258</p>	<p>1-6,9,            10,            12-17,            20-22,            24-31,            34,            36-42,            45,            47-56,            59,            61-63,            75,78,            81-83,            86,88,            89,130</p>
Y	<p>page 15779            page 15783, right-hand column, paragraph 1            - page 15784, right-hand column, paragraph 1;            figures 7C,8A</p>	<p>1-131</p>
X	<p>-----            CARRILLO JUAN J ET AL: "Measurement of agonist-dependent and -independent signal initiation of alpha(1b)-adrenoceptor mutants by direct analysis of guanine nucleotide exchange on the G protein galpha(11)."            THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. SEP 2002,            vol. 302, no. 3, September 2002 (2002-09),            pages 1080-1088, XP002297485            ISSN: 0022-3565</p>	<p>20-26</p>
Y	<p>page 1081            page 1082, left-hand column, paragraph 2 -            right-hand column, paragraph 1</p>	<p>11,35,            46,60,            70,87,            100,114,            127</p>
Y	<p>-----            GREASLEY P J ET AL: "Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling."            THE JOURNAL OF BIOLOGICAL CHEMISTRY. 7 DEC 2001,            vol. 276, no. 49,            7 December 2001 (2001-12-07), pages            46485-46494, XP002297486            ISSN: 0021-9258</p>	<p>7,8,18,            19,32,            33,43,            44,57,            58,67,            68,84,            85,97,            98,111,            112,124,            125</p>
	<p>-----            -/--</p>	

## INTERNATIONAL SEARCH REPORT

PCT /GB2004/002150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MILLIGAN G: "Oligomerisation of G-protein-coupled receptors." JOURNAL OF CELL SCIENCE. APR 2001, vol. 114, no. Pt 7, April 2001 (2001-04), pages 1265-1271, XP002297487 ISSN: 0021-9533 the whole document	1-131
Y	SEIFERT R ET AL: "GPCR-Galpa fusion proteins: molecular analysis of receptor-G-protein coupling" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 9, 1 September 1999 (1999-09-01), pages 383-389, XP004178196 ISSN: 0165-6147 the whole document	1-131
Y	GEORGE SUSAN R ET AL: "G-protein-coupled receptor oligomerization and its potential for drug discovery." NATURE REVIEWS. DRUG DISCOVERY. OCT 2002, vol. 1, no. 10, October 2002 (2002-10), pages 808-820, XP009036840 ISSN: 1474-1776 the whole document	1-131
A	MILLIGAN G: "Principles: Extending the utility of ' <sup>35</sup> S!GTPgammaS binding assays" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 2, February 2003 (2003-02), pages 87-90, XP004404399 ISSN: 0165-6147 the whole document	
P,X	CARRILLO JUAN J ET AL: "Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 24 OCT 2003, vol. 278, no. 43, 24 October 2003 (2003-10-24), pages 42578-42587, XP002297489 ISSN: 0021-9258 the whole document	1-131

INTERNATIONAL SEARCH REPORT

PCT/GB2004/002150

**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 132-144  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.2

Claims Nos.: 132-144

Present claims 132-144 relate to methods of treatment using structurally non-defined products (compounds) that are identified by certain biological tests described. These products are merely defined by a functional parameter or property, namely the ability to bind to the claimed molecules (e.g. to be ligands of the claimed molecules), to yield/modulate a biological activity, to affect levels of expression of or to act either agonistically or antagonistically towards the claimed molecules. The use of these parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, no search has been carried out for claims 132-144.

Moreover, the claims cover all products having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.